Podcasts about fda approval

Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements shaping the landscape of our industry. As technology continues to redefine traditional paradigms, the collaboration between Pfizer and Chai Discovery exemplifies this trend. By harnessing artificial intelligence, particularly through custom models like Chai-3, this partnership aims to revolutionize drug discovery. The integration of AI promises not only to accelerate the identification of biologics and antibodies but also to optimize resource allocation in research and development. Such technological integration could pave the way for an enhanced pipeline of innovative treatments, marking a transformative shift in how therapeutic candidates are developed. In the realm of regulatory developments, Lupin's Ranluspec has recently received FDA approval as an interchangeable biosimilar targeting VEGF-A for various retinal conditions. This move underscores the importance of biosimilars in providing cost-effective alternatives to expensive biologics, thereby expanding patient access to essential treatments for conditions like macular degeneration. Additionally, the MHRA's marketing authorization for Aujemflu, an adjuvanted trivalent influenza vaccine for adults aged 50 and over, reflects ongoing efforts to bolster protection against infectious diseases among vulnerable populations. Clinical trial advancements continue to highlight significant progress in therapeutic development. Otsuka Pharmaceuticals' Phase 3 data on Voyxact has shown promising stabilization of kidney function in patients with Immunoglobulin A nephropathy. This protein therapy targets autoimmune pathways, offering new hope for managing this chronic kidney condition. Similarly, Autobahn Therapeutics' Elunetirom has advanced to a pivotal trial following Phase 2 success in treating bipolar depression. This showcases the potential of small molecule therapies targeting thyroid hormone receptors. Meanwhile, Hikma Pharmaceuticals' victory in a landmark patent case regarding skinny labels marks an important development in pharmaceutical intellectual property rights. The unanimous Supreme Court ruling against Amarin supports the legitimacy of using skinny labels to market generic versions of drugs for non-patented indications. This decision could enhance market competition and drive down healthcare costs, setting a precedent for future intellectual property disputes. On the business front, strategic partnerships and mergers continue to shape industry dynamics. Gilead Sciences' acquisition of Ouro Medicines for $1.675 billion strengthens its autoimmune inflammation pipeline. This transaction exemplifies how major deals are reshaping therapeutic portfolios in response to growing demand for treatments targeting rare diseases. Financially, Solix Pharmaceuticals' success in raising $71 million to advance its siRNA pipeline across multiple therapeutic areas demonstrates investor confidence in RNA-based therapeutics as a promising frontier for innovative treatments. Conversely, challenges persist as evidenced by Takeda's $2.5 billion legal provision over an antitrust case related to Amitiza, underscoring ongoing financial risks associated with litigation in the pharmaceutical sector. Corporate restructuring also signals shifts within the industry landscape. Fulcrum Therapeutics' decision to lay off 85% of its workforce following the discontinuation of its sickle cell disease candidate highlights the volatility and high stakes inherent in drug development. Overall, these developments illustrate a dynamic landscape where scientific innovation is propelled by AI-driven approaches and strategic collaborations while regulatory victories and financial maneuvers shape market dynamics. These trends have profound implications for patient care by potentially accelerating the availability of novel therapies and fostering a competitive environment that drives down costs. As we look ahead, stakeholders must navigate these complexities effectively to harness opportunities and address challenges within this rapidly evolving industry landscape. The ability to adapt and capitalize on emerging trends will be crucial as these sectors continue to evolve, ultimately enhancing patient care and advancing therapeutic frontiers globally. Thank you for joining us today on Pharma Daily; stay tuned for more insights into the ever-changing world of pharmaceuticals and biotech.Support the show

In 2023, the FDA approved escitalopram (Lexapro) for generalized anxiety disorder (GAD) in children aged 7 and older, based largely on one industry-sponsored trial showing a small statistical edge over placebo on the Pediatric Anxiety Rating Scale (PARS). Critics argue the benefits fall below clinically meaningful thresholds while risks—particularly a roughly six-fold increase in treatment-emergent suicidal ideation—raise serious concerns about the risk-benefit balance. This episode explores the trial data, study limitations, broader context of pediatric antidepressant use, and what it means for families and clinicians navigating anxiety treatment options.

What if the biggest issues in dentistry are the ones you can't see? In this episode of the Raving Patients Podcast, Dr. Len Tau sits down with renowned prosthodontist and innovator Cherilyn Sheets to discuss how new diagnostic technology is changing the future of dentistry. Cherilyn shares the story behind Interview and Quantitative Percussion Diagnostics (QPD), a science-based system designed to detect cracks, loose restorations, implant instability, and structural weaknesses before they become catastrophic problems. Dr. Tau and Cherilyn explore how this technology helps dentists improve diagnostics, increase patient trust, and boost case acceptance by showing patients issues that traditional imaging often misses. They also dive into the intersection of dentistry, engineering, AI, and preventive care, along with the journey of bringing a groundbreaking dental innovation to market. From early diagnosis to patient communication, this conversation highlights how modern dentistry is moving beyond what can simply be seen on an X-ray. What You'll Learn How Quantitative Percussion Diagnostics (QPD) works Why traditional imaging can miss structural tooth problems How Interview technology helps improve case acceptance The role of AI and engineering in modern dental diagnostics How dentists can identify cracks, loose crowns, and implant instability earlier Why preventive intervention creates better patient outcomes How Cherilyn Sheets helped develop and commercialize this technology The importance of combining science, integrity, and innovation in dentistry — Key Takeaways 00:56 Introduction to Cherilyn Sheets and Interview Technology 03:30 What Interview Technology Actually Does 06:11 Who Benefits Most from QPD Diagnostics 08:42 How Technology Improves Case Acceptance 11:10 Understanding Quantitative Percussion Diagnostics (QPD) 14:52 Detecting Cracks, Stress, and Structural Problems Early 17:55 Comparing Interview to Other Diagnostic Technologies 18:35 Using QPD to Find Pain Sources Faster 19:16 Common Objections and Ease of Use in Practices 23:22 FDA Approval and Product Validation 25:29 The Story Behind the Technology's Creation 30:55 Why Interview Complements X-Rays Instead of Replacing Them 32:42 Cherilyn's Passion for Innovation and AI in Dentistry 33:45 Lightning Round Questions 40:30 Special Offer and How to Learn More About Interview 41:40 Final Thoughts and Episode Wrap-Up   — Connect with Cherilyn Website: Innerview AI - https://innerview.ai/ Email: cgsheets@ncofi.org Organization: Newport Coast Oral Facial Institute (NCOFI) — Learn proven dental marketing strategies and online reputation management techniques at DrLenTau.com. This podcast is sponsored by Dental Intelligence. Learn more here. This podcast is sponsored by CallRail, call tracking & lead conversion software for dentists. Find out more here. Raving Patients Podcast is your go-to place for the latest and best dental marketing strategies that will help you skyrocket your practice. Follow us for more!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the evolving landscape of the pharmaceutical and biotechnology industries, where scientific advancements, regulatory updates, and strategic business decisions are reshaping the future. A significant development in this dynamic arena is the strategic withdrawal by Eli Lilly and Boehringer Ingelheim from planned investments in Germany. Both companies have decided to cut at least $1 billion each from their investments, a direct response to Germany's healthcare reforms targeting reduced branded drug prices. This decision highlights how governmental policy can significantly influence pharmaceutical investment strategies, prompting companies to be more cautious in markets with strict pricing controls. Another critical area of focus is clinical trials, where ADC Therapeutics has encountered a significant challenge. The company's antibody-drug conjugate, Zynlonta, which was granted accelerated FDA approval in 2021, recently reported three times as many deaths in its study arm compared to the control group. This raises important questions about the safety profile of antibody-drug conjugates, a class of drugs celebrated for their potential in targeted cancer therapy. The situation underscores the ongoing struggle to balance efficacy with safety in innovative cancer treatments. Regulatory oversight remains a pivotal aspect of the industry. The FDA recently issued a warning letter to Medline over recurring issues with toxic bacteria in finished products, emphasizing the critical need for compliance and safety within the medical device sector. Additionally, an untitled letter was sent to QOL Medical for potentially misleading promotional communications regarding Sucraid. Such actions demonstrate the FDA's vigilance in monitoring marketing practices that could mislead healthcare providers or patients. In drug approval news, AbbVie's Qulipta and Amgen's Imdelltra have secured approvals in Europe. These milestones are part of a broader strategy by pharmaceutical companies to expand geographically and enhance product portfolios through new indications. Meanwhile, Axsome Therapeutics successfully defended its narcolepsy medication Sunosi against generic competition until 2040 by settling patent litigation with a prospective generic manufacturer. This move reflects the intense patent battles common in the industry to extend product lifecycles and maintain market exclusivity. Turning to geopolitical influences, there is heightened scrutiny on China's biotech sector following calls from U.S. lawmakers for increased oversight. The potential application of the Comprehensive Outbound Investment National Security Act to Chinese biotech investments signals escalating tensions and could significantly impact international collaborations and investments. This reflects growing concerns over intellectual property protection and biotechnological advancements within international trade dynamics. In financial developments, Parabilis Medicines is preparing for an IPO with aims to raise $476 million to fund Phase 3 trials of its desmoid tumor drug candidate. This move illustrates continued investor interest in oncology innovations despite broader economic uncertainties. On the scientific front, Autobahn Therapeutics is making strides with its thyroid hormone receptor stimulator, showing efficacy in reducing depression symptoms in bipolar disorder during Phase 2 trials. This success paves the way for pivotal trials and highlights how hormone mimics can offer new therapeutic avenues for neuropsychiatric disorders. Meanwhile, Alnylam Pharmaceuticals has entered into a groundbreaking $2 billion agreement with Inceptive Nucleics to incorporate artificial intelligence into small interfering RNA design. By leveraging AI-driven methodologies, Alnylam aims to enhance precision and efficacy in siRNA therapies, potentially speeding up drug discovery processes. Operational challenges are also evident as companies navigate complex markets like Japan, underscoring the importance of integrating regulatory and strategic planning early on to mitigate risks and ensure market feasibility. These developments paint a vivid picture of a vibrant pharmaceutical and biotech landscape where scientific innovation is rapidly advancing alongside strategic partnerships and regulatory oversight. Breakthrough technologies such as AI-driven drug design hold promise for more targeted therapies while emphasizing personalized medicine approaches. However, these advancements come with challenges like safety concerns and regulatory compliance that demand constant vigilance and adaptability from industry stakeholders. The implications for patient care are significant as these scientific breakthroughs promise new treatment avenues for complex diseases while highlighting personalized medicine approaches. As these industries continue to evolve, staying informed about scientific innovations and regulatory landscapes will be crucial for stakeholders aiming to drive future growth and improve global health outcomes. Thank you for tuning into Pharma Daily. Stay informed and stay ahead with us as we continue to bring you the latest insights from around the pharmaceutical and biotech world.Support the show

A Place Called Hope: Dr. Francisco Contreras on Cancer Care, Faith, and Integrative Healing Episode Description In this episode of Conversations with a Chiropractor, Dr. Stephanie Wautier sits down with Dr. Francisco Contreras of Oasis of Hope in Tijuana, Mexico, for a thoughtful and deeply meaningful conversation about cancer care, hope, faith, prevention, and whole-person healing. Dr. Contreras shares the story of Oasis of Hope, founded by his father, Dr. Ernesto Contreras, more than 60 years ago. What began as a vision to care for the physical, emotional, and spiritual needs of cancer patients has grown into an international integrative oncology center serving patients from around the world. Stephanie and Dr. Contreras talk about the importance of treating the whole person, not just the diagnosis. Their conversation moves through integrative cancer care, immune support, natural and conventional treatment options, nutrition, exercise, stress, spiritual strength, early detection, breast cancer screening, biopsy concerns, and the role of hope in the healing process. Dr. Contreras also discusses why he believes patients need clear, understandable information when facing cancer. With so much information online, the process can feel overwhelming and frightening. His message is steady and compassionate: cancer is serious, but it does not have to immediately steal a person's joy, clarity, or hope. This episode includes discussion of cancer treatment, prevention, screening, integrative oncology, COVID vaccination concerns, and medical decision-making. It is meant to inform, encourage, and spark deeper questions, not replace personal medical advice. Anyone dealing with cancer, screening decisions, treatment options, supplements, or major health changes should work directly with a qualified medical team that understands their individual situation. In This Episode, Discover The story behind Oasis of Hope and its 60-year history How Dr. Ernesto Contreras helped shape a whole-person approach to cancer care Why Dr. Francisco Contreras believes emotional and spiritual support matter in healing What integrative oncology means at Oasis of Hope Why some natural therapies are studied but not widely approved or adopted How immunotherapy and immune support fit into the Oasis of Hope approach Dr. Contreras' perspective on rising cancer rates in younger people Simple lifestyle steps that may help reduce cancer risk The importance of fruits, vegetables, movement, stress reduction, and spiritual strength Why cancer symptoms often appear after disease is already present Mammograms, ultrasound, MRI, thermography, and early detection How Dr. Contreras thinks about biopsy risk versus diagnostic benefit When someone might consider contacting Oasis of Hope Why clear information matters when patients are overwhelmed The role of hope, mindset, faith, and joy during a cancer journey Stay Connected & Explore Learn More About Dr. Francisco Contreras and Oasis of Hope: Oasis of Hope: https://www.oasisofhope.com/ Dr. Francisco Contreras: https://www.oasisofhope.com/doctor/dr-francisco-contreras/ Request a Free Consultation: https://www.oasisofhope.com/contact-us/ Download Dr. Contreras' Free Cancer E-Book, The Art & Science of Undermining Cancer: https://www.oasisofhope.com/ Episode Sponsor: Learn more about Lemongrove Oil: https://www.lemongroveoil.com/ Connect with Conversations with a Chiropractor: Follow Us on YouTube: http://www.youtube.com/@ConversationswithaChiro Follow Dr. Stephanie on Facebook: https://www.facebook.com/wautierwellness Email for show-related inquiries and sponsorships: drstephaniewautier@yahoo.com Want to be a guest on Conversations with a Chiropractor? Send Stephanie Wautier a message on PodMatch, here: https://www.podmatch.com/hostdetailpreview/drstephanie Credits Podcast production by Brand|Sound. Start your podcast journey by emailing brandsoundpodcasts@gmail.com. Chapters 00:00 Introduction to Conversations with a Chiropractor 04:03 Meet Dr. Francisco Contreras 04:21 The Story Behind Oasis of Hope 08:08 Cancer Care Statistics and a Different Approach 08:46 Integrative Oncology and Treatment Options 10:47 Natural Therapies, Research, and FDA Approval 11:38 Immunotherapy and the Immune System 12:45 Science, Natural Therapies, and Patient Care 15:20 Rising Cancer Rates in Younger People 17:56 COVID Vaccination Questions and Cancer Concerns 21:20 Early Warning Signs and Cancer Prevention 22:23 Fruits, Vegetables, Exercise, and Risk Reduction 24:27 Stress, Immunity, and Spiritual Strength 26:05 Keeping Wellness Simple and Sustainable 29:36 Breast Cancer Screening, Mammograms, and Thermography 33:07 Biopsy Concerns, Risk, and Diagnostic Benefit 36:19 When to Contact Oasis of Hope 38:47 Referrals, Free Consultations, and Becoming a Patient 39:32 Dr. Contreras' Books and Free Cancer E-Book 42:10 Cancer Is Not Necessarily a Death Sentence 43:37 Hope, Mindset, and the Power of Joy 45:22 Final Thoughts and Closing

Friday June 5, 2026 Replimune Gets Third Try at FDA Approval After Makary Departure

Most people assume that if a drug sits on the shelf at Costco or Walgreens, it must be pretty safe. But what if some of the most common over-the-counter (OTC) medications are among the riskiest drugs in America? On this vintage episode of Vitality Radio, Jared exposes the hidden dangers behind everyday pain relievers, sleep aids, and heartburn drugs—medicines that cause thousands of deaths every year when misused or taken long-term. You'll learn how a drug becomes “OTC,” what happens when pharmaceutical companies push for that switch, and why the FDA's approval process might not tell the whole story. Jared dives into the startling realities of PPIs like Prilosec, NSAIDs like ibuprofen, and acetaminophen (Tylenol)—uncovering their risks to the liver, kidneys, bones, and brain. He also discusses how marketing convinces consumers these drugs are harmless. Finally, Jared offers a resource for safe, natural alternatives for reflux, pain, inflammation, sleep, and immune support—options that nourish the body instead of depleting it. This episode will change the way you look at “harmless” OTC drugs and help you take real control of your health.Additional Information:#341: Your Digestive Health Supplement User's Guide. From IBS to Acid Reflux - Learn How to Balance Your Gut Health With Natural Products. #522: Q&A Show #5 - Jared Answers Your Questions About Energy and Sleep!#471: Boosting Your Immune System Ahead of Winter #553: Boswellia & Curcumin: Nature's Dream Team for Pain & Inflammation with Dr. Lexi LochVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

On this episode of Inside Startup Investing, Chris Lustrino speaks with Dr. Michael Wyand, CEO of Oxeia Biopharma, a clinical-stage biotech company developing a potential breakthrough treatment for concussions and persistent concussion symptoms. Oxeia is leveraging ghrelin, a naturally occurring hormone involved in brain energy regulation and neural repair, to help heal the inflammation and cellular damage caused by traumatic brain injuries. With promising Phase 2a data showing an 85% responder rate among treated patients, the company is pursuing what could become the first FDA-approved pharmaceutical treatment specifically targeting concussion recovery. Chris and Michael discuss the science behind concussions, how brain damage occurs after impact, why “just rest” has remained the standard of care for decades, and how Oxeia's therapy could fundamentally change the treatment landscape for athletes, veterans, and millions of patients suffering from lingering neurological symptoms. They also dive into the company's clinical pathway, the business opportunity behind concussion therapeutics, the role of neurogenesis in recovery, and the broader future potential for treating conditions like CTE, Parkinson's disease, and ALS. If you want to understand the future of concussion recovery, brain health innovation, and biotech investing, this is an episode you won't want to miss.

There's a single number on your routine blood test that predicts your risk of dying from cancer, heart disease, and infection better than cholesterol — and an FDA-approved drug may now move it.In this Health Longevity Secrets explainer, Robert Lufkin MD breaks down lymphopenia, the IL-15 cytokine, and ANKTIVA (nogapendekin alfa inbakicept) — the first FDA-approved IL-15 super-agonist and possibly one of the most important longevity drugs of the decade.CHAPTERS: 00:00 — Introduction: The Blood Test Number Better Than Cholesterol 00:35 — What Is Lymphopenia and Why It Matters 01:50 — Immunosenescence: Why Your T Cells Decline After Age 20 02:30 — The Mortality Data: Three Studies on Lymphopenia 03:20 — Copenhagen Study: 63% Higher All-Cause Mortality 03:50 — Coronary Angiography Study: Hazard Ratio 1.97 04:25 — Enter IL-15: The Cytokine That Builds Killer Immune Cells 05:15 — IL-15 as a Myokine: Why Resistance Training Protects Against Cancer 06:00 — Four Hallmarks of Aging Hit By One Molecule 06:30 — ANKTIVA Explained: The IL-15 Super-Agonist 07:00 — FDA Approval, Bladder Cancer, and the Soon-Shiong Reframe 08:15 — Is ANKTIVA a Longevity Drug? The Bullish Case 09:00 — The Skeptical Case: Why We Don't Know Yet 10:15 — What You Can Do Today: Track Your Number, Raise IL-15 Naturally 11:30 — Final Take and ClosingKEY TAKEAWAYS:Lymphopenia (absolute lymphocyte count below 1,500/μL) predicts all-cause mortality better than cholesterol in multiple large cohort studiesIL-15 expands NK cells and CD8+ T cells — the same cells that clear senescent "zombie" cells and patrol for cancerResistance training is the single strongest known endogenous IL-15 stimulus; your muscle signals your immune system to stay youngANKTIVA is the first FDA-approved IL-15 super-agonist (April 2024) — currently for bladder cancer but being reframed as a lymphopenia treatmentIL-15 hits four hallmarks of aging at once: immunosenescence, senescent cell accumulation, chronic inflammation, and sarcopeniaHonest take: exciting hypothesis with FDA approval, but zero human longevity trials yet — watch this spaceSTUDIES & SOURCES MENTIONED:Zidar et al., JAMA Network Open 2019 — Lymphopenia and mortality in 31,178 US adults (NHANES)Warny et al., CMAJ 2020 — Copenhagen General Population Study, lymphopenia in 108,135 adultsBawamia et al., Cardiology Journal 2022 — Lymphopenia and 8-year mortality in 15,179 coronary angiography patientsFDA approval, April 22, 2024 — Nogapendekin alfa inbakicept-pmln (ANKTIVA) for BCG-unresponsive non-muscle invasive bladder cancerWatch the full video on YouTube: https://youtu.be/220KHIdFCwg

Kelley Jensen, host of the Refrigerator Moms Podcast joins Shannon today to talk about TMS (Transcranial Magnetic Stimulation), a noninvasive brain stimulation therapy.  Today's jargon is Elopement. 00:00 Intro & Disclaimer 00:33 Show Overview & Guest Preview (TMS + Refrigerator Moms) 01:29 How to Watch & Engage (Live + YouTube + Podcast) 03:15 Ad-Free Subscription Option Explained 04:23 All Ghouls Gala Announcement (Autism Care Today Fundraiser) 05:01 Call to Action: Contact Governor Newsom 06:15 Proposed Medi-Cal Changes Impact Autism Care 08:23 Transportation Limits & Access to Treatment 10:05 Diagnosis Requirements & Waitlist Concerns 11:33 Personal Story: Early Intervention Success 13:39 Kevin Hart Roast Controversy & Autism Representation 16:05 Identity & Autism Community Discussion 17:23 "Patience" TV Show Recommendation (Autistic Representation) 19:54 Transition to TMS Interview 20:47 Guest Introduction: Kelly Jensen 21:22 What is TMS? (Transcranial Magnetic Stimulation Explained) 23:08 TMS Treatment Process & Safety 25:15 FDA Approval, Insurance, and Use Cases 27:12 What TMS Feels Like (Patient Experience) 28:44 Early Results & Behavioral Changes 30:18 Major Improvements in OCD & Anxiety 31:18 Continued Progress After Treatment 34:20 How TMS Impacts Brain Function 35:28 TMS + Therapy + Medication Benefits 37:13 Reduced Medication Use & Outcomes 38:00 Brain Performance Technologies Overview 40:12 FDA-Approved Conditions for TMS 42:10 Side Effects & Considerations 42:36 Why TMS Isn't Widely Used in Autism 43:58 Discussion: John Elder Robison & TMS Experience 47:15 How to Learn More About TMS 49:37 Refrigerator Moms Podcast Origin Story 52:29 What the Podcast Covers (Research + Parent Guidance) 58:31 Where to Listen & Watch 59:52 Jargon of the Day: Elopement Defined 01:01:24 Why Elopement Is a Major Safety Risk 01:02:25 STOP Method for Preventing Elopement 01:11:24 Closing Remarks & Resources

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries continues to evolve with significant scientific advancements, regulatory breakthroughs, and strategic maneuvers that are reshaping drug development and patient care. One of the noteworthy developments is the U.S. FDA's recent approval of Gilead Sciences' Hepcludex (bulevirtide) for hepatitis D. This approval marks a comeback for Gilead after previous setbacks due to manufacturing and delivery issues, highlighting the critical importance of addressing regulatory feedback. It's a testament to persistence in overcoming manufacturing challenges to ensure vital therapies reach those in need. This approval signifies a milestone as it's the first FDA-approved therapy targeting chronic hepatitis D virus infection—a niche condition with limited treatment options. Similarly, Pfizer's Braftovi (encorafenib) is expanding its global reach beyond U.S. borders with regulatory approvals in the EU and Canada for colorectal cancer treatment. This broadening geographic footprint reflects a broader industry trend where companies aim to maximize the therapeutic impact of oncology drugs across diverse patient populations. Meanwhile, Astellas Pharma is navigating the looming patent cliff for its prostate cancer drug Xtandi by actively pursuing new licensing deals and implementing cost-cutting measures. This dual approach underscores a widespread industry strategy where companies balance acquisitions with operational efficiency to sustain growth. In the radiopharmaceutical sector, there's notable activity with Lantheus Holdings possibly being acquired by Curium for $7 billion. This potential deal underscores growing interest in radiopharmaceuticals due to their precision in targeting specific cancer types. Complementing this is Niowave's $75 million investment in a radiopharmaceutical isotope plant in Michigan, set to produce actinium-225 by 2028—an isotope crucial for targeted cancer therapies. Regulatory landscapes are also in flux with continued reforms at the FDA despite leadership changes. Initiatives like the Commissioner's National Priority Voucher program illustrate regulatory bodies' commitment to streamlining drug approvals and fostering innovation. On an international note, SK Bioscience is partnering with Colombia to locally produce the chickenpox vaccine Skyvaricella, enhancing vaccine accessibility through technology transfer. Similarly, Eli Lilly's acquisition spree in infectious disease research signals a robust push toward expanding its R&D pipeline for viral and bacterial pathogens. Eli Lilly has announced plans to acquire Curevo, Limmatech Biologics, and another vaccine company for up to $3.8 billion. This strategic acquisition underscores a commitment to enhancing capabilities in infectious diseases—a field that has gained focus post-COVID-19 pandemic. By integrating these companies, Eli Lilly aims to leverage their platforms and expertise for advanced therapeutic solutions against infectious diseases. In gene editing, Eli Lilly is preparing for a Phase 2 trial of a lipid-lowering gene editor from Verve Therapeutics, showing promising cholesterol reductions akin to PCSK9 inhibitors. This highlights gene editing's potential in addressing cardiovascular diseases. A significant development from Lilly's pipeline includes promising results from their base editor technology acquired through Verve Therapeutics—an exciting breakthrough suggesting substantial potential for gene-editing technologies addressing genetic disorders like high cholesterol. In oncology, AstraZeneca and Daiichi Sankyo's Datroway gained FDA approval for triple-negative breast cancer as a first-line treatment. This antibody-drug conjugate targets Trop2, demonstrating the potential of targeted therapy in difficult-to-treat cancers. Kura Oncology's combination therapy featuring darlifarnib and Krazati showed up to a 69% response rate in KRAS G12C-mutated solid tumors during Phase 1 trials, emphasizing precision medicine's potential in targeting specific genetic mutations driving cancer progression. In obesity management, Eli Lilly's retatrutide achieved Phase 3 success with bariatric surgery-like outcomes. The drug acts as a triple hormone receptor agonist, showcasing advancements in metabolic therapies targeting obesity—a condition linked with numerous comorbidities. Moderna's mFlusiva is poised for an FDA advisory committee review as an influenza preventative for older adults—an extension of Moderna's mRNA technology initially used against COVID-19. Collectively, these developments highlight an industry leveraging cutting-edge science and technology to tackle complex medical challenges. As pharmaceutical giants like Eli Lilly consolidate their positions through acquisitions and research collaborations, transformative advancements promise to reshape patient care across various therapeutic areas. These initiatives not only reflect the industry's dynamic nature but also its pivotal role in addressing unmet medical needs worldwide. Eli Lilly's recent strategic acquisitions underscore its commitment to advancing pharmaceutical innovations, particularly in vaccines and cholesterol management sectors. Acquiring three vaccine-focused biotech firms signifies substantial investment in expanding its vaccine portfolio—a move aligned with global immunization strategies. This follows hiring Peter Marks from the FDA, indicating a strategic focus on bolstering expertise within the vaccine domain. The company has been recognized by IDEA Pharma as a leader in pharmaceutical innovation—a testament to its robust pipeline and successful integration of scientific advancements into marketable therapies. Across oncology landscapes highlighted at ASCO conferences are exciting potentials like Summit Therapeutics and Akeso's potential Keytruda rivals that could reshape cancer treatment paradigms if proven effective. As pharmaceutical landscapes continue evolving rapidly through scientific strides tempered by regulatory hurdles—the current environment promises significant advancements offering new hope while demanding strategic agility within healthcare sectors globally.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of noteworthy advancements and challenges that are shifting the landscape of drug development and patient care. Starting with AstraZeneca and Daiichi Sankyo, their Trop2-directed antibody-drug conjugate, Datroway, has secured FDA approval for first-line treatment in triple-negative breast cancer. This form of cancer is notoriously aggressive and offers limited treatment options, making this approval a significant milestone. It positions Datroway as a key player in the ADC market targeting TNBC, highlighting the increasing role of antibody-drug conjugates in oncology. This advancement not only expands therapeutic options for patients but also emphasizes the growing importance of ADCs in effectively targeting cancer cells while sparing healthy tissues. In another exciting development, Merck and Kelun Biotech have reported on their SAC-TMT ADC, which when paired with Keytruda, shows a profound impact on PD-L1-positive non-small cell lung cancer patients. Their combination therapy demonstrated a remarkable 65% reduction in disease progression or death compared to Keytruda alone. Presented at the ASCO annual meeting, these findings could potentially revolutionize first-line treatments for NSCLC, further underscoring the promising therapeutic potential of combining ADCs with immunotherapies. However, AstraZeneca faced a setback with a novel breast cancer drug as an FDA advisory committee recommended against its approval. Interestingly, the European Medicines Agency provided a favorable opinion, illustrating the divergent regulatory landscapes across continents. Such discrepancies highlight the complex regulatory environment pharmaceutical companies must navigate and could influence strategic decisions regarding market focus. On the legal front, Eli Lilly is embroiled in controversy over an alleged $200 million rebate fraud scheme involving its diabetes drug, Trulicity. This situation sheds light on ongoing issues within pharmaceutical distribution channels and raises questions about compliance and oversight mechanisms necessary to prevent such financial misconduct. Meanwhile, industry dynamics continue to evolve as AbbVie announced workforce reductions in its Allergan Aesthetics unit. This move reflects broader trends where companies streamline operations to prioritize core competencies and promising therapeutic areas. From a regulatory perspective, Maat Pharma's decision to seek re-examination for its graft-versus-host disease medication underscores the iterative nature of drug approval processes. Persistence in addressing regulatory feedback remains crucial as companies strive for successful market entry. In obesity management, Novo Nordisk's oral GLP-1 receptor agonist, Wegovy, gains traction as a convenient treatment option. The shift towards oral medications could significantly improve patient adherence and outcomes by offering an easier alternative to injections. Biogen's decision to terminate its collaboration with Denali Therapeutics after unsuccessful phase 2 trials for a Parkinson's disease candidate highlights the inherent risks in neurological drug development. Rigorous clinical evaluation remains essential to ensure efficacy before advancing therapies further. Despite these advancements, challenges persist as Biogen and Denali's BIIB122 failed in phase 2b trials for idiopathic Parkinson's disease. This underscores the complexity of neurological disorders and emphasizes the need for continued innovation targeting LRRK2 kinase inhibitors. In the realm of CAR-T therapies, Novartis' T-Charge platform faces competition from emerging in vivo technologies. This competitive landscape demonstrates rapid evolution within cell therapy domains, aiming to enhance efficacy and accessibility for patients. Meanwhile, strategic mergers and acquisitions continue as Liminatus Pharma acquires CAR-T biotech Innocsai for $320 million, underscoring sustained interest in oncology cell therapies. Switching gears to Eli Lilly's recent Phase 3 TRIUMPH-1 trial results for retatrutide, they reveal promising weight loss outcomes comparable to bariatric surgery. As a triple hormone receptor agonist targeting GLP-1, retatrutide holds significant potential in addressing obesity—a condition with profound public health implications. Medtronic's acquisition of SPR Therapeutics to enhance its chronic pain portfolio reflects a focus on minimally invasive treatments. Financially, Research Alliance III raised $75 million through a SPAC IPO targeting mergers with China-based biotech firms, signaling increased global collaboration within the sector. Dandelion Health's $14 million Series A funding aims to advance clinical intelligence platforms that could transform drug development through data analytics. Finally, Moderna's mRNA-based flu vaccine is set for review by the FDA's vaccine advisory committee after overcoming initial regulatory hurdles. This scrutiny highlights ongoing challenges faced by novel vaccine technologies within rigorous regulatory environments. In summary, these developments illustrate an industry at the forefront of scientific innovation while grappling with regulatory complexities and operational challenges. From antibody-drug conjugates and immunotherapy combinations to gene editing and advanced cell therapies, there's a clear commitment to improving patient outcomes through novel scientific approaches. As these trends evolve, they promise to redefine treatment landscapes across various therapeutic areas—offering new opportunities for scientific advancements and enhanced patient care worldwide.Support the show

Full article: Utilization of Pediatric Contrast-Enhanced Ultrasound in the United States After FDA Approval: Insights From a Large Claims Database Regulatory approval alone is insufficient to drive clinical adoption. Selima Siala, MD, is joined by Marcelo Takahashi, MD, to discuss the AJR article by Guarilha et al. that explores the trajectory of national utilization of contrast-enhanced ultrasound in children.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest news shaping the industry, from breakthroughs in cancer therapies to advancements in AI-driven drug discovery. Starting with regulatory updates, the potential appointment of Richard Pazdur, M.D., as the new FDA Commissioner is causing quite a stir. Following Marty Makary's resignation, Pazdur has emerged as a prominent candidate due to his extensive background in oncology drug regulation. Known for his commitment to accelerating cancer therapy approvals, his potential leadership could maintain or even amplify the focus on expediting innovative treatments for cancer patients. In a significant regulatory achievement, Beone Medicines celebrated the FDA's approval of Beqalzi, marking it as the first BCL-2 inhibitor approved for mantle cell lymphoma. This approval challenges AbbVie's Venclexta and underscores a growing trend towards targeted cancer therapies that offer new treatment avenues for patients. The oncology space continues to be fiercely competitive, with companies striving to deliver more precise and effective cancer treatments. Turning to clinical trials, AstraZeneca's Imfinzi has shown promising results in a phase 3 trial focused on bladder cancer patients who are not eligible for cisplatin-based chemotherapy. These findings position Imfinzi as a strong competitor to Merck's Keytruda and reinforce AstraZeneca's strategic focus on expanding its oncology portfolio through novel combinations and indications. In the realm of genetic therapies, Regenxbio has achieved a milestone with its gene therapy for Duchenne muscular dystrophy. This therapy met its primary endpoint in pivotal trials, highlighting the potential of gene therapies to address rare diseases with limited treatment options. Such successes are likely to encourage further investment in gene editing technologies, which hold significant promise for tackling conditions once deemed untreatable. The FDA is also exploring frameworks to repurpose existing drugs for new uses by leveraging existing safety data. This could streamline drug development processes and offer cost-effective solutions for patients with complex conditions. However, this approach will need rigorous validation of efficacy in new indications to ensure patient safety and therapeutic effectiveness. Despite setbacks in its Alzheimer's research, Biogen remains steadfast in its efforts. While their tau-targeting candidate did not meet primary endpoints in a phase 2 trial, reductions in tau pathology and cognitive benefits were observed. This perseverance showcases Biogen's commitment to finding innovative approaches to tackle Alzheimer's disease despite ongoing challenges. On the operational front, Taiwan's Bora Group is acquiring Macrogenics' CDMO operations for up to $127.5 million. This move reflects a broader trend of consolidation within the CDMO space as companies aim to enhance their production capabilities and streamline operations. Quality control remains a critical concern as evidenced by Sun Pharma's recent recall of a chemotherapy batch due to glass particle contamination. Incidents like these underline the importance of stringent quality assurance measures throughout the manufacturing process to ensure patient safety. Moreover, Viz.ai has launched an AI-powered pulmonary care platform aimed at integrating acute and chronic care workflows. This development signals an increasing adoption of artificial intelligence in healthcare, promising improvements in diagnostics and patient management efficiency. AI continues to gain traction as Isomorphic Labs recently secured $2.1 billion in Series B funding aimed at enhancing AI-driven drug design models. Similarly, Charles River has introduced an AI-powered digital pathology platform poised to Support the show

Kevin Sabet debates Matt Johnson on the Illusion of Consensus podcast with host Rav Arora, covering Trump's psychedelic executive order, ibogaine, FDA approval, Right to Try, drug scheduling, and the future of psychedelic research. Sabet, a former White House drug policy advisor across the Clinton, Bush, and Obama administrations, argues for caution around psychedelics, marijuana policy, commercial incentives, and overstated medical claims. Johnson, a leading Johns Hopkins psychedelic researcher, responds on psilocybin studies, addiction treatment, depression, safety protocols, REMS, and why accelerated research may still follow the evidence. The discussion also covers Joe Rogan, RFK Jr., Marty Makary, Jay Bhattacharya, ketamine clinics, MDMA, MAPS, cannabis rescheduling, veteran suicide, and the risks of turning experimental drugs into public policy too quickly. Subscribe to Rav's Substack to get episodes straight to your inbox: https://www.illusionconsensus.com Chapters: 0:00 - Intro 2:05 - Sabet's Objection to Psychedelics 10:00 - Matt's Disagreement with Sabet 13:15 - Psychedelic Research Quality 21:10 - Kevin's Rebuttal 24:00 - Was Joe Rogan Wrong On Ibogaine's Efficacy 32:50 - Ibogaine Safety Concerns 40:50 - Could The Executive Order Go Too Far 46:10 - Rescheduling and FDA Approval

In today's episode, we welcomed Luhua (Michael) Wang, MD, to discuss the implications of the full FDA approval of brexucabtagene autoleucel (Tecartus; brexu-cel) for the treatment of adult patients with relapsed/refractory mantle cell lymphoma (MCL). Dr Wang is a professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine, as well as a professor in the Department of Stem Cell Transplantation at The University of Texas MD Anderson Cancer Center in Houston.On April 2, 2026, the FDA granted traditional approval to brexu-cel based on data from the phase 2 ZUMA-2 trial (cohorts 1 and 2, NCT02601313; cohort 3, NCT04880434), with confirmatory data from cohort 3 showing that patients naive to a BTK inhibitor experienced an overall response rate (ORR) of 91% (95% CI, 82.5%-95.9%), a complete response (CR) rate of 79% (95% CI, 69.0%-87.1%), and a median duration of response (DOR) that was not reached (NR; 95% CI, 26.2 months-not evaluable).Dr Wang detailed the evolution of therapies in the MCL treatment paradigm, leading up to the approval of brexu-cel and the integration of CAR T-cell therapy. Along with highlighting the evolution of MCL management, Dr Wang explained how data from cohort 3 of ZUMA-2 add further context to the role of CAR T-cell therapy in the treatment paradigm and how it may affect treatment sequencing considerations.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode dives into the ever-evolving landscape of the pharmaceutical and biotechnology industries, which are experiencing significant transformations driven by scientific advancements, strategic realignments, and regulatory changes. Sanofi is making a significant move by investing $294 million to expand its AI center of excellence in Toronto. This investment is part of a broader trend in the sector to optimize pharmaceutical operations and accelerate drug development through digital transformation. By enhancing its AI capabilities, Sanofi aims to streamline processes and reduce time-to-market for new drugs, positioning itself as a leader in this digital era. In clinical trials, Cytokinetics has reported a pivotal success with MyoKardia's drug Myqorzo in a Phase 3 trial aimed at treating non-obstructive hypertrophic cardiomyopathy. If approved, Myqorzo would be the first treatment available for this condition, highlighting ongoing efforts within the industry to address unmet medical needs with innovative therapies. However, not all ventures meet expectations. Pfizer's acquisition of Trillium Therapeutics for $2.3 billion did not materialize as hoped, leading to the discontinuation of its remaining clinical-stage candidates. This outcome underscores the risks inherent in pharmaceutical investments and the importance of thorough evaluation of potential therapeutic candidates. Similarly, Vertex Pharmaceuticals encountered challenges with its inhaled cystic fibrosis candidate developed with Moderna due to tolerability issues, highlighting patient safety's role in clinical trials. Strategic shifts are also taking place in workforce management. BioNTech plans to cut 1,860 jobs as it exits manufacturing sites in Germany and Singapore, reflecting broader industry trends toward operational optimization. Similarly, Novartis is closing its manufacturing site in Wehr, Germany, resulting in 220 job cuts as part of efforts to streamline operations. Regulatory developments continue to shape industry dynamics. Axsome Therapeutics received FDA approval for Auvelity as a treatment for agitation associated with Alzheimer's disease. This not only enhances Axsome's market potential but also underscores the critical role of regulatory agencies in facilitating access to treatments for complex conditions. Moreover, CAR-T therapies are expanding beyond oncology into autoimmune diseases. Kyverna Therapeutics is advancing toward a groundbreaking approval for CAR-T therapy in autoimmune disorders, marking an evolution in therapeutic applications. The recent developments underscore a dynamic phase characterized by technological innovation and strategic restructuring. AI technologies are revolutionizing drug discovery processes while successful clinical trials expand treatment options for previously unmet needs. Yet challenges remain with investment risks and organizational realignments reshaping operational strategies. Pfizer's discontinuation of its investment in Trillium Therapeutics due to inadequate clinical results emphasizes the necessity for robust data to support therapeutic viability. On a regulatory front, Strand Therapeutics stresses reforming the FDA's Investigational New Drug process to maintain U.S. leadership in biomedical innovation amid global competition. Passage Bio's strategic review following regulatory setbacks with its gene therapy program further exemplifies biotechnological unpredictability. Viridian Therapeutics' success with its anti-IGF-1R antibody bodes well for FDA approval and competition against established players like Amgen. The formation of the American Biotech Innovation Alliance signifies efforts to unify domestic biotech strategies amid global competition. Investments continue despite these challenSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant updates that highlight the dynamic nature of our industry, driven by cutting-edge science, regulatory evolution, and strategic business innovations. The pharmaceutical landscape is ever-shifting, with recent developments underscoring this fluidity. Pfizer and Arvinas have secured early FDA approval for their breast cancer drug, Veppanu. This move signals the FDA's growing inclination to fast-track promising therapies, particularly in areas with high unmet needs. Interestingly, Pfizer and Arvinas are opting not to commercialize Veppanu independently and are instead seeking a partner. This decision reflects a broader industry trend where biopharmaceutical companies leverage partnerships to maximize the reach and impact of their therapies. Such strategies are becoming increasingly common as companies navigate complex market dynamics. Legal and healthcare domains intersected dramatically when the U.S. Supreme Court temporarily restored online access to the abortion pill mifepristone. This decision underscores the profound influence of legal rulings on healthcare access and distribution channels within the pharmaceutical sphere in the United States. It's a poignant reminder of how regulatory decisions can ripple through healthcare systems, affecting both providers and patients. Meanwhile, Samsung Biologics faces significant financial repercussions—estimated at $102 million—due to an ongoing union strike. This situation reveals vulnerabilities within contract development and manufacturing organizations (CDMOs) regarding labor relations, emphasizing the need for robust operational strategies to maintain production continuity. In a move that underscores its commitment to biologics manufacturing, Amgen announced a $300 million investment in Puerto Rico. This expansion aligns with growing global demand for biologics and biosimilars and highlights Puerto Rico's strategic importance as a pharmaceutical manufacturing hub, thanks to its favorable business environment and skilled workforce. On a different front, Novartis is optimizing its workforce by implementing additional job cuts at its U.S. headquarters. These adjustments are part of a larger multiyear plan aimed at streamlining operations and reallocating resources towards areas with higher growth potential within its portfolio. The potential resurgence of psychedelics is gaining traction, partly fueled by political support from figures like Donald Trump. The regulatory landscape for psychedelics remains complex, with discussions focusing on their therapeutic potential versus societal acceptance and legitimacy concerns. In the competitive weight-loss drug market, Novo Nordisk's Wegovy pill is currently outperforming Eli Lilly's Foundayo in prescription trends. This rivalry highlights the dynamic nature of the GLP-1 receptor agonist segment—a market experiencing rapid growth due to increasing attention on obesity management as a critical public health issue. Deloitte's latest analysis reveals an intriguing shift: obesity drugs have now overtaken oncology as the leading contributor to late-stage pipeline value for the first time in 16 years. This transition underscores a growing recognition of obesity as an essential therapeutic area with significant market potential, driven by advances in drug efficacy and heightened patient demand. Celcuity has reached a pivotal milestone in breast cancer treatment development with its Phase 3 trial success of a pan-PI3K/mTOR inhibitor against Novartis' Piqray. Achieving primary endpoints positions Celcuity favorably for FDA review, further highlighting continuous innovation within oncology research. UCB's acquisition of Candid Therapeutics for $2 billion exemplifies intensified competition Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a fascinating array of industry shifts and scientific breakthroughs that are shaping the future of medicine and patient care. Sun Pharma's acquisition of Organon for $11.75 billion is making waves as it marks a significant expansion for the Indian pharmaceutical giant into international markets. This deal not only amplifies Sun Pharma's footprint but also integrates Organon's strong focus on women's health and biosimilars into its portfolio. It's a strategic move that underscores the increasing trend of cross-border mergers as companies seek to diversify and enhance their global presence. As the largest-ever overseas acquisition by an Indian firm, this transaction is emblematic of the growing importance of global consolidation in the pharma industry. Meanwhile, Astellas Pharma faces a mixed fiscal outlook with its prostate cancer drug Xtandi. While Xtandi experienced a modest sales increase in 2025, a projected decline for 2026 has prompted Astellas to pivot towards developing new medicines. This highlights the critical dependence on innovation within the industry to sustain growth, especially as competition intensifies. In the realm of ATTR amyloidosis treatments, Pfizer has reached a settlement with two generic manufacturers over its drug Vyndamax. This resolution is crucial in stabilizing the market amidst rising generic competition, which can significantly influence pricing and market dynamics. Such settlements are an integral part of maintaining competitive positioning in crowded therapeutic spaces. Ligand Pharmaceuticals' strategic purchase of XOMA for $739 million signals a broader trend of consolidation among biotech royalty aggregators. This acquisition aligns with Ligand's strategy to augment its portfolio through mergers and acquisitions—a recurring theme as biotech companies strive to streamline operations and expand their competitive edge. The competition within the oral GLP-1 market is intensifying, particularly with Eli Lilly's delayed launch of Foundayo inadvertently benefiting Novo Nordisk's market position. This rivalry underscores the fierce race to dominate the lucrative obesity management sector, highlighting how pivotal timing can be in gaining market share. The FDA's recent allocation of national priority vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics marks a significant regulatory shift towards embracing psychedelic therapies. These vouchers could expedite development timelines, thereby accelerating patient access to novel treatments that have traditionally been underexplored. Thermo Fisher Scientific's robust start to 2026 showcases how strategic acquisitions like that of Clario can drive growth. This reflects broader industry trends where biopharma companies leverage technological advancements to enhance capabilities in clinical trial support and data management. In gene editing news, Intellia Therapeutics is advancing towards FDA approval for its in vivo CRISPR therapy following successful Phase 3 trials. This progress heralds a new era for gene editing technologies in treating genetic disorders, underscoring their potential to revolutionize therapeutic approaches. Eli Lilly continues its aggressive acquisition strategy by purchasing Ajax Therapeutics for $2.3 billion. This acquisition focuses on next-generation JAK inhibitors for myelofibrosis, aligning with Lilly's broader goal to diversify its pipeline and maintain its leadership in innovative therapeutics. Recent studies have also shed light on how an endoscopic procedure used in Europe can aid patients on Eli Lilly's tirzepatide in maintaining weight loss post-treatment. This finding could significantly impact long-term obesity management strategies, offering new insights into sustainaSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're exploring a fascinating realm where technology and biology converge, starting with a deepening relationship between biopharma and artificial intelligence. Novartis CEO Vas Narasimhan's recent appointment to the board of AI company Anthropic signals the strategic integration of AI into drug discovery and development processes. This collaboration highlights a growing trend where pharmaceutical companies are increasingly leveraging AI to optimize clinical trials, streamline drug discovery, and personalize patient care strategies. Similarly, Novo Nordisk has announced a strategic partnership with OpenAI to integrate AI technologies across various facets of its operations, including drug discovery and manufacturing. By leveraging OpenAI's machine learning capabilities, Novo Nordisk aims to streamline research efforts and accelerate therapeutic identification—a collaboration reflecting AI's growing role as an essential tool for maintaining competitiveness in drug development. Additionally, Amazon Web Services' launch of the Amazon Bio Discovery AI tool marks another milestone. Designed to expedite antibody design and drug discovery processes, it provides researchers with robust AI-driven platforms enhancing therapeutic design speed and accuracy. The emphasis on monoclonal antibodies aligns with industry trends focusing on targeted therapies for diseases such as cancer. Meanwhile, Eli Lilly's new obesity treatment, Foundayo, has caught the FDA's attention due to potential safety concerns. Despite progressing with its launch, the FDA has requested additional safety information to address unexpected serious risks associated with the drug. This highlights the ongoing regulatory scrutiny that accompanies novel treatments, especially in areas like obesity where patient populations are large and diverse. In another strategic move, Eli Lilly's acquisition of Crossbridge Bio for up to $300 million aims to bolster its oncology pipeline with dual-payload antibody-drug conjugates (ADCs). This acquisition reflects a strategic move enhancing Eli Lilly's position in oncology by integrating cutting-edge ADC technologies known for delivering cytotoxic agents directly to cancer cells while minimizing off-target effects. On another front, Travere Therapeutics is mapping a pathway to a potential $3 billion opportunity in the U.S. market following significant approval for its treatment Filspari, targeted at rare kidney diseases. This approval underscores the increasing focus on rare diseases, which present lucrative opportunities for pharmaceutical companies due to significant unmet needs and often high-cost treatments. Astellas' manufacturing strategy underscores the importance of reliable supply as a critical bridge from research to patient care. Led by Chief Manufacturing Officer Rao Mantri, this strategy highlights how manufacturing excellence can significantly impact drug availability and patient outcomes. It emphasizes that production reliability is vital in ensuring groundbreaking research translates into accessible medical treatments. In contrast, a slowdown in IPOs has been noted amidst an aggressive merger and acquisition spree by major pharmaceutical companies. This consolidation trend reflects strategic shifts within the industry as companies seek to bolster pipelines through acquisitions rather than organic growth. Such dynamics indicate a strategic pivot as firms prioritize acquiring promising assets over developing them from scratch. Ionis Pharmaceuticals' recent win in a drug naming competition exemplifies the complexities involved in branding within the pharmaceutical sector. Crafting a drug name that is memorable yet distinctive involves balancing marketability with regulatory requirements—a reflection of the intSupport the show

In this special “Ask the Expert” collaboration between The MOG Project and SRNA, Julia Lefelar and Dr. GG deFiebre welcomed Dr. Benjamin Greenberg of UT Southwestern, who answered questions from the audience. Dr. Greenberg reviewed major advances in MOG antibody disease research and diagnostic criteria [00:05:06]. He discussed efforts to predict relapse risk using sustained antibody positivity, demographic and clinical models, and immune-cell profiling studies [00:07:55]. Dr. Greenberg detailed controversies around low-positive antibody titers and how cell-based assays and dilution thresholds affect specificity [00:21:38]. He outlined concepts and progress in tolerance-inducing approaches such as Tregs and CAR T therapy, described differences from B-cell–depleting drugs like rituximab [00:26:32] Finally, Dr. Greenberg highlighted the satralizumab meteoroid trial and the ongoing cosMOG study of rozanolixizumab, emphasizing community engagement, registries, surveys, and trial participation to accelerate access and potential curative strategies [00:38:36]. You can learn more about The MOG Project here:https://mogproject.org/Benjamin M. Greenberg, MD, MHS is a Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology [ https://utswmed.org/why-utsw/departments/neurology/ ] at UT Southwestern Medical Center in Dallas, Texas. He currently serves as the Vice Chair of Translational Research and Strategic Initiatives for the Department of Neurology. He is also the interim Director of the Multiple Sclerosis Center [ https://utswmed.org/locations/aston/multiple-sclerosis-and-neuroimmunology-clinic/ ] and the Director of the Neurosciences Clinical Research Center. In addition, he serves as Director of the Transverse Myelitis and Neuromyelitis Optica Program and the Pediatric Demyelinating Disease Program at Children's Medical Center [ https://www.childrens.com/specialties-services/specialty-centers-and-programs/neurology/demyelinating-disease-program ].Dr. Greenberg earned his medical degree at Baylor College of Medicine before completing an internal medicine internship at Chicago's Rush Presbyterian-St. Luke's Medical Center. He performed his neurology residency at the Johns Hopkins School of Medicine. He also holds an M.H.S. in molecular microbiology and immunology from the Bloomberg School of Public Health, as well as a bachelor's degree in the history of medicine – both from Johns Hopkins. Prior to his recruitment to UT Southwestern in 2009, Dr. Greenberg was on the faculty of the Johns Hopkins Division of Neuroimmunology, serving as the Director of the Encephalitis Center and Co-Director of the nation's first dedicated Transverse Myelitis Center.Dr. Greenberg splits his clinical time between adult and pediatric patients at William P. Clements Jr. and Zale Lipshy University Hospitals, Parkland, and Children's Medical Center. His research focuses on better diagnosing, prognosticating, and treating demyelinating diseases and nervous system infections. He also coordinates clinical trials to evaluate new treatments to prevent neurologic damage and restore function to affected patients.00:00 Welcome01:44 Hosts and Guest Intro05:06 Research Buckets Overview07:55 Predicting Relapse Risk11:46 Tregs and Immune Brakes17:40 Attack Severity and Relapse19:24 MOGAD Criteria Updates21:38 Titers Explained Simply26:32 Targeting MOG Antibodies29:11 CAR T and Immune Reset32:39 When Criteria Changes33:52 Tolerance Research Boom34:48 From Animals to Trials37:17 Community Drives Progress38:36 Meteoroid and cosMOG Clinical Trials41:39 How These Drugs Work44:02 FDA Approval and Access45:49 Insurance Switch Concerns48:39 Rituximab Dosing Debate52:41 Why Antibodies Develop54:18 Future Attack Patterns55:47 CAR T Versus Rituximab57:10 Lab Research and Support01:00:51 Hope for a Cure01:02:14 Closing and Resources

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most intriguing advancements and strategic moves shaping the future of drug development and patient care. Regeneron has recently ventured into the radiopharmaceuticals market through a substantial $2.1 billion agreement with Australia's Telix Pharmaceuticals. This move marks a significant diversification from Regeneron's traditional focus, such as obesity treatments, to an area that combines radioactive isotopes with targeting molecules for diagnosing and treating diseases like cancer more effectively. The strategic alliance positions Regeneron as a formidable player in this emerging field, promising to expand its therapeutic portfolio and revenue streams. In oncology innovation, GSK is pushing forward with a bold initiative, conducting Phase 3 trials for antibody-drug conjugates (ADCs) in collaboration with Hansoh Pharmaceutical. This effort underscores GSK's commitment to expanding its oncology pipeline, particularly in targeting unmet medical needs through innovative therapies. Antibody-drug conjugates are designed to deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues and offering a precision approach to cancer treatment. Allogeneic CAR-T therapies are also making waves, with Allogene Therapeutics reporting promising early data from their off-the-shelf CAR-T therapy, cema-cel. This therapy effectively eradicated minimal residual disease in lymphoma patients, highlighting the potential of allogeneic approaches to provide accessible cancer treatments without the logistical complexities of autologous methods. In another significant milestone, Ideaya Biosciences, in collaboration with Servier, achieved success with their eye cancer drug candidate meeting its primary endpoint in a crucial Phase 2/3 trial. This success sets the stage for an accelerated FDA approval filing, offering new hope for patients dealing with this challenging condition. Revolution Medicines has made notable progress in oncology as well, with its highly anticipated RAS inhibitor demonstrating improved survival outcomes in a Phase 3 trial for pancreatic cancer. Extending survival by an average of six months compared to chemotherapy could redefine treatment paradigms for one of the most aggressive cancer types. Not every development has been favorable, however. Replimune faced its second FDA rejection for its melanoma candidate RP1, leading to workforce reductions—a testament to the rigorous nature of regulatory approvals and the challenges companies face when bringing novel therapies to market. Meanwhile, BioNTech and Synox Therapeutics are advancing towards FDA approval for their tumor-targeting therapies. These efforts could intensify competition within the oncology space, challenging established giants like AstraZeneca and Daiichi Sankyo. In pain management, AbbVie has expanded its portfolio through a $745 million deal with Haisco Pharmaceutical Group for two non-opioid pain treatment candidates. This move aligns with growing demand for non-opioid alternatives amid the opioid crisis, reflecting a strategic shift towards safer pain management solutions. Spyre Therapeutics has also reported positive Phase 2 results for its ulcerative colitis drug, setting it up as a potential competitor against Takeda's Entyvio. Success here could enhance therapeutic options for patients struggling with this chronic condition, highlighting continued innovation in gastrointestinal disorders. Eli Lilly's recent success with its BTK inhibitor Jaypirca marks a pivotal moment in chronic lymphocytic leukemia (CLL) treatment strategies. Having demonstrated substantial efficacy in a Phase 3 clinical trial—the fourth positive readout—Jaypirca establishes itself as an industry first. Its fixed-duratioSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of dynamic changes and strategic shifts reshaping these industries, driven by scientific advancements and regulatory updates. Let's start with Biogen, which recently resolved an investor lawsuit concerning its Alzheimer's drug, Aduhelm. Approved under controversial circumstances by the FDA, Aduhelm faced scrutiny for its efficacy and costs. This settlement is a critical reminder of the importance of transparent communication with investors, especially when navigating high-stakes therapeutic areas like Alzheimer's. The broader implication for pharmaceutical companies is the need to balance innovation with accountability and transparency—a challenge that resonates across the industry. Meanwhile, Pfizer's decision to vacate office space in South San Francisco exemplifies a significant trend toward remote work, accelerated by the COVID-19 pandemic. This shift suggests that traditional workplace models are being reassessed in favor of flexibility and cost efficiency, a change likely to influence real estate investments and organizational structures across biotech firms. Amgen stands out with its notable financial growth highlighted by CEO Robert Bradway's $24.7 million compensation package in 2025. This success underscores Amgen's strategic prowess in maintaining robust performance amidst competitive pressures. Their approach could serve as a blueprint for other firms aiming to achieve sustained growth through innovation and strategic management. On the clinical trial front, Insmed's decision to halt development of Brinsupri after underwhelming mid-stage results illustrates the inherent risks in drug development. This highlights the need for rigorous trial designs and adaptive strategies within development pipelines to address potential setbacks efficiently. Turning to Gilead Sciences, there's a strategic pivot from mergers and acquisitions towards strengthening its internal research pipeline, now described as stronger than ever. This shift away from external acquisitions reflects an industry trend prioritizing internal R&D capabilities, potentially leading to breakthrough therapies that enhance patient care while ensuring sustained business growth. In regulatory developments, GSK's Exdensur received new approval in China, showcasing the ongoing globalization of pharmaceutical markets. Navigating diverse regulatory environments becomes crucial for maximizing drug accessibility worldwide. Another trend is seen through Invivyd's “Antibodies for Any Body” campaign featuring Olympic skier Lindsey Vonn. Leveraging public figures can significantly raise awareness about innovative treatments, playing a crucial role in educating the public about medical advancements. There's also significant financial movement within the sector as Jeito Capital announced a record $1.2 billion fundraising for an independent biopharma-focused European fund. This capital influx is poised to accelerate research and development activities across Europe, potentially leading to new therapeutic breakthroughs. Vivtex Therapeutics' $2.1 billion deal with Novo Nordisk illustrates the power of strategic collaborations in advancing therapeutic solutions and enhancing drug delivery systems—key components for improving patient outcomes. Sidewinder Therapeutics is making strides with a $137 million funding round to develop antibody-drug conjugates (ADCs), highlighting investor confidence in technologies that integrate precision medicine approaches to offer potent cancer treatments with reduced side effects. Astellas Pharma's collaboration with Dyno Therapeutics marks another milestone in gene therapy advancements. A $15 million agreement aims at utilizing engineered adeno-associated virus (AAV) capsids for muscle disorders, proSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of remarkable advancements and challenges shaping these dynamic sectors. AstraZeneca has reported promising results with an immunotherapy combination involving Imfinzi (durvalumab) and Imjudo (tremelimumab) for treating locoregional liver cancer. This combination has demonstrated a significant progression-free survival benefit, potentially setting a new standard in liver cancer treatment. The success of this regimen highlights the critical role of immunotherapies in oncology, offering new hope for patients with cancers that have been historically difficult to treat. Turning to regulatory news, Eli Lilly's new GLP-1 receptor agonist pill, Foundayo, has received FDA approval. This marks a significant milestone as it's the first new molecular entity approved under the FDA's National Priority Voucher Program. Foundayo's approval intensifies the competition in the obesity treatment market, challenging Novo Nordisk's established position with Wegovy. Analysts forecast a major rollout for Foundayo, predicting over 5 million prescriptions by 2026. This advancement underscores the increasing focus on addressing obesity, a critical global health challenge. In geopolitical news, former U.S. President Donald Trump is reportedly considering imposing a 100% tariff on certain pharmaceutical imports from non-Most Favored Nation countries. Such a policy could significantly impact international pharmaceutical trade and supply chains, forcing companies to reevaluate their global manufacturing and distribution strategies. In vaccine development news, a Belgian court has ordered Poland and Romania to pay Pfizer $2.2 billion over contested COVID-19 vaccine doses, underscoring the complexities of international vaccine agreements and their financial ramifications during the pandemic. Conversely, Pfizer and BioNTech have halted their US Phase 3 trial for the Comirnaty COVID-19 vaccine due to recruitment challenges. This reflects ongoing difficulties in maintaining participant engagement for booster studies post-pandemic. On the clinical trial front, Valneva's Lyme disease vaccine program with Pfizer remains a topic of interest despite missing its primary endpoint in Phase 3 trials. Valneva's CEO remains optimistic about its regulatory future, framing it as a matter of negotiation. This situation highlights the intricate nature of clinical trial outcomes and regulatory negotiations. Meanwhile, Gilead Sciences has faced setbacks with its HIV drug pipeline due to an ongoing FDA clinical hold on a mid-stage trial. This incident underscores the challenges companies encounter while navigating regulatory hurdles to ensure drug safety. In other industry trends, there's an increased reliance on pharmacovigilance outsourcing to enhance efficiency within pharmaceutical companies. This allows firms to concentrate more on core activities impacting patient care and drug innovation directly. The industry also saw exciting advancements in radioligand therapy, which holds promise for targeting up to 80% of cancers with precision therapies. Such developments illustrate how understanding biological pathways can lead to significant breakthroughs in cancer treatment paradigms. In business developments, Axsome Therapeutics has partnered with Takeda for Balipodect, a schizophrenia asset involving undisclosed payments. This partnership highlights the trend towards strategic collaborations in neurological disorders aimed at fostering therapeutic innovation. Furthermore, Zai Lab and Amgen are collaborating on a global Phase 1b trial focusing on small cell lung cancer using antibody-drug conjugates and bispecific T-cell engagers. This research emphasizes growing interest in precision oncology treatments offering targeted therapeutic oSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events shaping the industry, from groundbreaking drug approvals to strategic corporate maneuvers.Recently, the U.S. Food and Drug Administration (FDA) granted approval for Eli Lilly's new GLP-1 receptor agonist pill, Foundayoby, marking a significant milestone as it's the first new molecular entity to be cleared under the FDA's Commissioners National Priority Voucher Program. This program is designed to expedite the review process for drugs addressing critical needs or representing substantial advancements in treatment. Foundayoby's entry into the market provides a competitive edge against Novo Nordisk's products, offering a convenient oral alternative in the management of type 2 diabetes and obesity. Clinical trials have shown that this oral formulation maintains efficacy comparable to injectable peptides while improving patient adherence due to its ease of use. This development not only broadens therapeutic options but also emphasizes the growing trend towards patient-centric formulations in diabetes management.In related news, Eli Lilly has also received FDA approval for its oral obesity medication, Orforglipron, marketed as Foundayo. This approval further intensifies the rivalry with Novo Nordisk, which launched its oral therapy Wegovy earlier. Orforglipron's clinical trials demonstrated significant weight reduction in patients, highlighting pharmacotherapy's rising importance as an option for individuals struggling with obesity despite lifestyle modifications. The convenience of an oral formulation is expected to enhance patient compliance and long-term success, addressing a key challenge in obesity management.In strategic corporate news, Korsana Biosciences is making waves by entering public markets through a reverse merger with Cyclerion. This move highlights ongoing interest and investment in neurodegenerative diseases like Alzheimer's. In contrast, KBP Biosciences faces legal challenges as it seeks to reclaim ownership of heart drug Ocedurenone from Novo Nordisk after a failed billion-dollar deal. Such cases underscore the complexities inherent in pharmaceutical collaborations.Regulatory scrutiny continues to play a crucial role in shaping industry dynamics. The FDA extended its review period for Orca Bio's novel cell therapy for blood cancers by three months. This delay reflects rigorous regulatory requirements for innovative treatments poised to transform oncology care paradigms. Meanwhile, Iterum Therapeutics is winding down operations following unsuccessful sales of its antibiotic Orlynvah, highlighting financial sustainability challenges within the antibiotic market.Safety remains paramount as evidenced by concerns over Amgen's Tavneos after reports of serious liver injuries linked to its use. The FDA has identified 76 cases, including fatalities, underscoring the importance of post-market surveillance and risk management in ensuring patient safety.In terms of mergers and acquisitions, Eli Lilly's strategic acquisition of Centessa Pharmaceuticals for $6.3 billion signifies its entry into the sleep disorder market. Biogen followed suit by acquiring Apellis Pharmaceuticals for $5.6 billion to strengthen its kidney disease expertise. These moves reflect a broader trend where pharmaceutical giants are diversifying portfolios through acquisitions targeting niche therapeutic areas.On the technological front, partnerships leveraging artificial intelligence (AI) are gaining traction. Bristol Myers Squibb's collaboration with Faro Technologies aims to refine clinical trials using AI, while Merck & Co.'s partnership with Infinimmune focuses on antibody discovery innovations.Financially, Blackstone's record-breaking $6.3 billion life sciences fund highlights robust invSupport the show

Hey friends,Dr. Yi Song has spent her career bridging Eastern and Western medicine.What she's found is that most people are already losing the health game before they feel a single symptom.In this conversation, Dr. Song breaks down why treating symptoms is not the same as healing, what stem cell therapy can actually do (and what the industry gets dangerously wrong), and how meditation and energy flow aren't just ancient metaphysics - they're measurable, teachable tools for longevity.If you've ever wondered whether regenerative medicine is real or hype, or how to find a clinic you can actually trust, this episode will sharpen your thinking.Key Topics:* Why early prevention is the most overlooked lever in healthcare* Stem cell types, functions, and what mesenchymal stem cells can treat* How stem cell production declines with age — and what to do about it* Navigating the unregulated stem cell clinic landscape safely* The six principles of natural longevity from The Regeneration Effect* Meditation, energy flow, and metaphysical states of consciousnessTimestamps:* 00:00 The Intersection of Eastern and Western Medicine* 08:05 The Importance of Early Prevention in Healthcare* 13:19 Exploring Stem Cell Therapy and Its Benefits* 16:18 Understanding Stem Cells: Types and Functions* 19:56 Applications of Mesenchymal Stem Cells in Treatment* 22:39 Preventative Measures for Joint Health and Aging* 28:05 The Decline of Stem Cells with Age* 29:17 Skepticism and FDA Approval in Stem Cell Therapy* 30:58 Quality Control in Stem Cell Treatments* 33:45 Identifying Reputable Clinics for Stem Cell Therapy* 35:21 The Importance of Personalized Treatment* 38:12 The Regeneration Effect: Principles for Longevity* 40:46 Six Principles for Health and Longevity* 46:24 Rapid Fire Longevity Questions* 49:52 Myths and Realities of Stem Cell TherapyRESOURCES MENTIONED:The Regeneration Effect Book — https://book.regenerationeffect.comStemCell Therapy Experts — https://stemcelltherapyexperts.comCell Therapy Experts Podcast — https://youtube.com/CellTherapyExpertsFree Regeneration Effect eBook — https://gift.regenerationeffect.comConnect with Dr. Song: https://regenerationeffect.comABOUT DR. YI SONG: Dr. Yi Song is a regenerative medicine physician and author of The Regeneration Effect. Drawing on decades at the intersection of Chinese medicine and modern science, she guides patients through personalized stem cell protocols and holistic longevity frameworks at StemCell Therapy Experts.ABOUT NINA'S NOTES: Nina's Notes explores the intersection of longevity science, neuroscience, and human optimization. Hosted by Nina Patrick, PhD in pharmaceutical sciences and longevity researcher, each episode translates cutting-edge research into actionable insights for living longer, better.CONNECT WITH NINA'S NOTESLinkedIn: https://www.linkedin.com/in/ninapatrick/Website: https://www.ninapatrick.xyzKey Wordsholistic health, early prevention, stem cell therapy, meditation, longevity, Chinese medicine, regenerative medicine, energy flow, aging, biohacking Get full access to Nina's Notes at www.ninasnotes.xyz/subscribe

Welcome to OncLive On Air®! I'm your host today, Kyle Doherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, we spoke with David Morris, MD, FACS, and Alan H. Bryce, MD. Dr Morris is the president of Urology Associates, PC, in Nashville, Tennessee. Dr Bryce is a medical oncologist and the chief clinical officer of City of Hope Cancer Center Phoenix in Arizona.In our exclusive interview, Drs Morris and Bryce discussed the clinical implications of the FDA's full approval of rucaparib (Rubraca) for BRCA mutation–associated metastatic castration-resistant prostate cancer (mCRPC), including the notable data that supported the regulatory decision and how this agent fits into the mCRPC treatment paradigm.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative developments that underscore the continual evolution of this dynamic industry.First, let's explore the latest strategic move from Takeda Pharmaceuticals, which has embarked on a $1.3 billion restructuring plan in the United States. This has resulted in layoffs affecting 634 employees, a decision aimed at streamlining operations and cutting annual costs by over $1.26 billion. Such significant restructuring efforts are likely to alter market dynamics, as Takeda reallocates resources to focus on its core competencies and innovation-driven growth. The industry may witness shifts as Takeda aims to bolster its competitive edge amid a rapidly evolving market landscape.In a significant regulatory development, Biogen has successfully secured FDA approval for a high-dose version of Spinraza, designed to treat spinal muscular atrophy (SMA). This approval, following the resolution of prior manufacturing concerns, is a strategic effort to enhance therapeutic efficacy and maintain Biogen's competitive positioning against newer market players. The high-dose formulation of Spinraza promises improved patient outcomes, reinforcing Biogen's dedication to addressing unmet medical needs in SMA and offering hope to patients and families affected by this debilitating condition.Meanwhile, Samsung Biologics faces internal challenges as its labor union votes in favor of striking over unresolved governance issues and rigid labor policies. This potential strike highlights growing tensions within the company and raises concerns about operational continuity, which could affect production timelines and contractual obligations with partners. It's a reminder of the delicate balance between corporate governance and employee relations within major organizations.On the innovation front, Idorsia's investigational drug Quviviq has shown promise in treating pediatric insomnia following successful Phase 2 trials. If approved, Quviviq could be a pioneering treatment for children with insomnia, setting a new standard of care for this underserved patient population. This development highlights the importance of addressing specific medical needs across different demographics within the broader field of sleep disorders.Financial investments in research and development continue to shape the industry, with Eli Lilly embracing insilico medicine's AI technology through a $2.75 billion collaboration. This partnership aims to leverage AI-driven insights for drug discovery, reflecting an industry-wide trend toward integrating digital technologies into R&D processes. By adopting AI, companies like Eli Lilly are poised to accelerate drug discovery timelines and enhance precision in identifying potential therapeutic candidates. Additionally, Eli Lilly is spearheading research efforts into GLP-1 receptor agonists for treating substance use disorders, based on emerging scientific evidence suggesting these compounds could play a role in managing addiction by modulating reward pathways linked to addictive behaviors.In cardiovascular health advancements, Boston Scientific's Watchman heart implant has demonstrated substantial clinical benefits by reducing bleeding risks compared to traditional anticoagulants while maintaining non-inferiority in stroke prevention and mortality outcomes among atrial fibrillation patients. This advancement is likely to influence future clinical practice guidelines by offering safer long-term management options for atrial fibrillation.Moreover, Advocate Health's ambitious hospital drone delivery program, in partnership with Zipline, seeks to revolutionize logistics within healthcare delivery systems across major U.S. cities. By enhancing supply chain efficiencies and ensuring timely access to critical Support the show

In today's episode, we spoke with Julia Rotow, MD, and Martin Dietrich, MD, PhD. Dr Rotow is the clinical director of the Lowe Center for Thoracic Oncology and director of clinical research at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School in Boston, Massachusetts. Dr Dietrich is a medical oncologist with The US Oncology Network Cancer Care Centers of Brevard and an assistant professor of internal medicine at the University of Central Florida College of Medicine in Orlando.In our exclusive interview, Drs Rotow and Dietrich discussed the significance of the accelerated FDA approval of zongertinib (Hernexeos) for patients with HER2 TKD–mutated non–small cell lung cancer (NSCLC). They highlighted how this approval addresses a longstanding unmet need in a patient population that historically relied on chemotherapy-based approaches.They noted that the introduction of zongertinib into the frontline setting represents a meaningful shift toward upfront biomarker-driven care, aligning HER2-positive disease with other oncogene-driven lung cancers where targeted therapies are used upfront.The discussion also focused on efficacy findings from the pivotal phase 1b Beamion LUNG-1 trial (NCT04886804). In previously untreated patients with HER2 TKD mutations, zongertinib generated an objective response rate of 76% (95% CI, 65%-85%). The treatment also showed encouraging durability, with 64% of responders having a duration of response (DOR) lasting at least 6 months and 44% of responders having a DOR lasting at least 12 months. Regarding safety, Rotow and Dietrich explained that zongertinib was designed as a HER2-selective inhibitor, potentially minimizing off-target EGFR-related toxicities. The most common adverse effects included low-grade diarrhea, rash, and liver enzyme elevations, with interstitial lung disease occurring infrequently. Notably, no significant signal for cardiac toxicity was observed, distinguishing zongertinib from some other HER2-directed therapies. Finally, the experts underscored the importance of comprehensive biomarker testing to identify HER2 alterations and ensure that patients can benefit from these expanding targeted treatment options.

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (3/26/26). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v75hm4a","div":"rumble_v75hm4a"}); Source Links (In Chronological Order):  (7) The Last American Vagabond on X: "@DBrozeLiveFree One of MANY obvious and well-documented cases of Americans being illegally detained or abused by ICE. https://t.co/hhurrVqnej" / X DHS Lies About Detaining/Deporting US Citizens & Trump Reportedly Readying To Attack Venezuela New Tab (7) The Last American Vagabond on X: "@DropSiteNews I am glad you guys are covering this, it needs more attention. Here is TLAV's coverage on this story from February: https://t.co/jVJjiONeZa" / X She uncovered a terrifying lab hidden in California, with alleged ties to China - Los Angeles Times Israeli Citizen Charged In The Las Vegas "Biolab" Case As Fort Detrick Investigates Sabotage (7) Las Vegas Locally

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the fast-paced changes shaping these sectors, focusing on the latest scientific breakthroughs, regulatory shifts, and industry trends.First off, Denali Therapeutics has achieved a significant milestone with FDA approval for its enzyme replacement therapy targeting Hunter syndrome, a rare genetic disorder. This therapy addresses neurological complications that have been challenging to treat, marking a pivotal moment for the rare disease community. Hunter syndrome is characterized by enzyme deficiencies leading to harmful accumulations in the body. The availability of this treatment not only provides new hope for patients but also underscores the potential of targeted therapies to manage complex neurological symptoms effectively.In oncology, Corcept Therapeutics has secured FDA approval for Lifyorli (relacorilant), designed for platinum-resistant ovarian cancer patients who have already undergone multiple lines of systemic treatment. This approval highlights the critical importance of strategic clinical trial design and persistent regulatory engagement, expanding treatment options for a patient population with limited alternatives.Meanwhile, Ionis Pharmaceuticals made headlines by slashing the annual price of Tryngolza by 93% ahead of its intended label expansion for severe hypertriglyceridemia. This strategic move aims to make the drug more accessible and capture a broader market share while addressing pricing pressures from regulators and patients alike. Such pricing strategies might set new precedents in the industry, particularly for drugs initially developed for rare diseases now targeting more common conditions.The funding landscape presents challenges as biopharma investment has dropped 20% in 2025. Companies are now prioritizing high-impact projects over broader portfolios, reflecting a shift towards focused R&D investments. This cautious climate may accelerate breakthroughs in prioritized areas yet poses risks if diversification is neglected.Regulatory dynamics are also in flux. The departure of Dr. Robert Malone from the CDC's Advisory Committee on Immunization Practices highlights ongoing tensions within vaccine advisory panels. These developments underscore the intricate balance between scientific evidence, public health policy, and stakeholder communication in guiding vaccine-related decisions.Technological advancements continue to reshape operations within life sciences companies. AI-driven platforms are playing a vital role in enhancing Medical-Legal-Regulatory processes by offering adaptable solutions that transcend traditional automation limits. This innovation is crucial for organizations aiming to optimize regulatory compliance while maintaining operational efficiency.In medical devices, Philips' AI-powered cath lab copilot has gained FDA clearance in collaboration with Edwards Lifesciences. This technology assists in transcatheter mitral valve repair—a complex procedure requiring precision and real-time data analysis—illustrating how AI can significantly enhance procedural outcomes and patient safety.Shifting focus to genetic therapies, Beam Therapeutics has shown promising progress with its base editing technology for alpha-1 antitrypsin deficiency (AATD), potentially revolutionizing treatment approaches for genetic disorders. Similarly, Sarepta Therapeutics is advancing RNA-based treatments with positive biomarker data for muscular dystrophies, reinforcing RNA therapies as viable alternatives or complements to traditional gene therapies.However, not all news is positive. Wave Life Sciences faced a setback when its obesity drug candidate showed only a modest reduction in body weight over six months. This highlights the competitive pressures and high expectations within metabolic disoSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.The pharmaceutical and biotech sectors are navigating a period of profound transformation, marked by significant scientific developments, regulatory challenges, and strategic realignments. In 2025, several major pharmaceutical companies collectively reduced their workforce by over 22,000 employees. This was a strategic response to the looming $300 billion patent cliff, which is expected to significantly impact the sector as numerous high-revenue-generating drugs lose patent protection. Such workforce reductions highlight the industry's need to innovate rapidly to offset potential revenue losses.In a pivotal legal development, a massive class action lawsuit seeking RICO penalties against Takeda and Eli Lilly has been allowed to proceed by the Supreme Court. This decision underscores the increasing legal scrutiny pharmaceutical companies face over their business practices. Should the prosecution succeed, substantial financial penalties could be imposed on these companies, potentially reshaping corporate governance and compliance frameworks across the industry.In terms of drug development and acquisitions, Gilead Sciences' $2.2 billion acquisition of Ouro marks a strategic pivot towards autoimmune therapeutics. This acquisition enriches Gilead's portfolio with a promising autoimmune T-cell engager and revitalizes its partnership with Galapagos, a Belgian biotech firm. Such deals are crucial as companies seek to bolster their pipelines with innovative therapies addressing unmet medical needs.Karyopharm's recent mixed results from its Phase 3 trial of Expovio in combination with Jakafi for treating myelofibrosis illustrate the complexities and challenges inherent in oncology drug development. The company plans to engage with the FDA to discuss these outcomes, indicating a cautious yet hopeful approach toward potential approval. This scenario underscores the high-stakes environment of clinical trials where mixed results can significantly influence regulatory decisions and market strategies.Meanwhile, Eli Lilly's decision to withdraw certain insulin products from European markets by 2027 reflects shifts in strategic priorities amidst regulatory pressures and market dynamics in Europe. This move may indicate a broader trend of pharmaceutical companies reassessing product portfolios in response to evolving healthcare policies and market demands.The year also saw WuXi Biologics expanding its project portfolio significantly with U.S. clients, despite geopolitical uncertainties. This trend highlights the increasing globalization of drug development and manufacturing processes, driven by a growing demand for contract research, development, and manufacturing services.On the technology front, artificial intelligence continues to reshape various facets of the life sciences industry. AI-driven platforms are not only optimizing engagement strategies but also enhancing operational efficiencies within life sciences teams. These tools offer flexibility that allows organizations to adapt workflows according to specific needs rather than being confined by rigid systems.However, challenges remain as evidenced by Aardvark's decision to halt trials for its obesity candidate due to cardiac concerns. This pause reflects ongoing safety challenges in drug development that necessitate robust risk management strategies.In financial developments, Wilmington PharmaTech's commitment of $50 million towards expanding its API production capacity in Delaware signals confidence in future demand for complex custom APIs. However, NIH grant cuts disproportionately affecting women and early-career scientists raise concerns about diversity and sustainability within the scientific workforce.The strategic investments continue as Novartis announces a substantial commitmeSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a range of topics that illustrate the rapidly changing landscape of our industry. We'll discuss everything from vaccine expansions to regulatory challenges, highlighting both the breakthroughs and hurdles faced by companies worldwide.Kicking off with GSK's recent achievement, their respiratory syncytial virus (RSV) vaccine, Arexvy, has gained FDA approval for adults aged 18 to 49 at increased risk of lower respiratory tract disease. This marks a significant milestone not only for GSK but also in the competitive RSV vaccine market where Pfizer and Moderna have already made their mark. This development underscores the industry's ongoing commitment to preventing RSV-related complications, reflecting the fierce competition driving innovation in vaccine development.In parallel, Gilead Sciences is making strides with its HIV pre-exposure prophylaxis medication, Yetztugo. The emphasis here is on how early production strategies can set a medication up for success by ensuring accessibility. This focus on manufacturing highlights a broader trend where efficient production methods are key to delivering timely healthcare solutions, underscoring the integral role manufacturing plays in modern drug development.Legend Biotech is navigating the competitive dynamics of the CAR-T therapy market with its treatment, Carvykti, despite facing competition from Johnson & Johnson's bispecific antibody Tecvayli. This scenario highlights strategic partnerships and market positioning challenges within oncology treatments, illuminating the complex landscape companies must navigate to succeed.On the regulatory front, Hyloris Pharmaceuticals encountered a setback when the FDA issued a Complete Response Letter due to manufacturing issues with its antiviral valacyclovir oral suspension. This incident serves as a reminder of the stringent manufacturing standards regulatory bodies demand and the essential nature of compliance in successful drug development.In an exciting advancement out of China, Neuracle Technology has developed the country's first brain-computer interface implant for paralyzed patients. This pioneering neurotechnology involves implanted EEG electrodes connected to a robotic glove capable of grasping objects. Such innovations highlight China's increasing role in cutting-edge medical technology development and represent a significant leap forward in rehabilitation for patients with severe disabilities.However, not all news is positive. Immutep faced an unexpected phase 3 failure with its LAG-3 candidate, which surprised analysts and led to a stock decline. These outcomes underscore the inherent risks in drug development and stress the importance of rigorous clinical evaluation to ensure both efficacy and safety.Shifting focus to diabetes management, companies like Insulet, Abbott, and Dexcom are expanding their efforts toward personalized care through continuous glucose monitors (CGMs) and insulin pumps. These advancements are part of an ongoing trend toward personalized diabetes management tools aimed at improving glucose control for patients.Meanwhile, Simtra Biopharma Solutions received an FDA warning due to contamination issues at one of its production facilities. This serves as a stark reminder of how crucial it is to maintain high-quality standards in drug manufacturing processes to avoid disruptions and ensure patient safety.Strategically speaking, we see notable shifts as companies like Eli Lilly invest in Asia and Pfizer enters obesity treatment markets through strategic partnerships. These moves highlight globalization trends as pharma companies seek to address high unmet medical needs in emerging markets.In a significant transition for BioNTech, founders Ugur Sahin and Ozlem Tureci are preparing to leave Support the show

Lots of FDA approval updates to discuss from the past few weeks: -Zongertinib gets approved in 1st line setting for ERBB2 TKD mutated metastatic NSLCLC -Encorafenib approval with cetuximab + FOLFOX -Teclistamab + Daratumumab approved in 2nd line setting for r/r multiple myeloma -Acalabrutinib + venetoclax (but NOT acalabrutinib + venetoclax + obinutuzumab) is approved for CLL Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm

Arthur Spalding, TAMM Net, Inc., contract research organization, on FDA Approval, Clinical Trials, and Reimbursement for Medical Devices and Biotech (North Fulton Business Radio, Episode 944) On this episode of North Fulton Business Radio, host John Ray welcomes Arthur Spalding, President of TAMM Net, Inc., a boutique contract research organization that helps biomedical inventors and companies […]

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of multiple myeloma treatment, focusing on the groundbreaking MajesTEC-3 trial. We had the pleasure of welcoming Dr. Luciano Costa from the University of Alabama, who shared insights on the combination of teclistamab and daratumumab for relapsed refractory multiple myeloma. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics discussed included: The impressive progression-free survival (PFS) rates observed in the MajesTEC-3 trial, with a PFS of 83.4% at three years. The mechanism of action of teclistamab as a bispecific antibody targeting BCMA and its synergy with daratumumab. Safety profiles, including the management of cytokine release syndrome (CRS) and infection risks, along with the use of IVIG for prophylaxis. The evolving landscape of multiple myeloma therapies, including the role of CAR T-cell therapy versus bispecific antibodies. Join us for this informative discussion that aims to keep healthcare professionals updated on the latest advancements in multiple myeloma treatment. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #MultipleMyeloma, #MajesTEC3, #Teclistamab, #Daratumumab, #BispecificAntibody, #OncBrothers

In today's episode, we welcomed Saad Z. Usmani, MD, MBA, FACP, FASCO, to discuss the significance of the January 2026 FDA approval of daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).Usmani is chief of Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York, and the recipient of the 2025 Giants of Cancer Care award for multiple myeloma.In the exclusive interview, Dr Usmani explained the clinical implications of the regulatory decision that expanded the indication for daratumumab plus VRd to the transplant-ineligible setting, detailed the pivotal data from the phase 3 CEPHEUS trial (NCT03652064) that supported the approval, and provided context for treatment strategies with this regimen in clinical practice.

I'm joined by Dr. Heather Hirsch to debunk the persistent myths surrounding hormone replacement therapy and explain why the 2002 Women's Health Initiative data was so widely misinterpreted. We discuss how optimized estrogen, progesterone, and testosterone levels can protect your heart, bones, and brain health, helping you move past "normalized suffering" and into a proactive state of longevity. Whether you are in perimenopause or well past the ten-year window, you'll learn how to navigate personalized dosing and clinical data to reclaim your vitality and extend your health span.Want ad-free episodes? Subscribe to Forever Strong Insider: https://bit.ly/4u5VSReListen to “Women's Health by Heather Hirsch, MD” on all your favorite platforms!Apple Podcasts: https://bit.ly/4l86MlwSpotify: https://bit.ly/4cpmiHuGet Dr. Heather Hirsch's book, “The Perimenopause Survival Guide” here:https://bit.ly/4r2yXUd

This interview is disseminated on behalf of GT Biopharma. GT Biopharma (NASDAQ: GTBP) recently received approval from the U.S. Food and Drug Administration (FDA) for a new investigational drug trial for the solid tumor cancer treatment GTB-3650, as the race to develop a cure for cancer intensifies and the solid tumor market grows to $362 billion.Executive Chairman and Chief Executive Officer Michael Breen shares more details about the company's expectations and success indicators for the basket trial of the new medication, as well as upcoming milestones for 2026.Explore GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/VtISaFICJ5gAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of transformative events shaping the industry, from regulatory approvals and licensing deals to clinical trial outcomes and strategic partnerships, each carrying profound implications for drug development and patient care.Starting with the biopharma landscape in China, there's a notable shift in the valuation of licensing deals, which have seen a significant increase of 230% in upfront payments. This surge, from $52 million to $172 million between 2022 and early 2026, signals China's growing influence and competitiveness in the sector. Historically considered a low-cost option for licensing deals, China's enhanced innovation capabilities are now attracting Western companies seeking strategic collaborations. The implications are vast, offering Western firms an opportunity to tap into China's expansive market potential and leverage local expertise, underscoring the country's pivotal role in global drug development.In regulatory news, Pfizer's Braftovi (encorafenib) combination therapy has achieved full FDA approval for colorectal cancer treatment. This is a critical development, expanding therapeutic options for a particularly challenging cancer type. The approval highlights the increasing importance of targeted therapies in oncology, reflecting ongoing efforts to address unmet medical needs by enhancing the treatment arsenal available to clinicians. As cancer remains a major global health issue, such advancements are vital for improving patient outcomes.Novartis is making headlines with its substantial investment strategy to boost radiopharmaceutical production capabilities in the United States. With new manufacturing sites planned in Texas and Florida as part of a broader $23 billion investment, Novartis is positioning itself at the forefront of radiopharmaceuticals—a field offering innovative cancer treatments through targeted radiation delivery. This strategic move not only strengthens Novartis's presence in this burgeoning field but also signifies a broader industry trend towards cutting-edge technologies that promise more precise and effective treatment modalities.Shifting focus to drug pricing dynamics, Novo Nordisk has announced plans to reduce list prices for its GLP-1 medications, Ozempic and Wegovy, starting next year. While self-pay channels remain unaffected, this price reduction reflects broader industry trends towards addressing medication costs amidst mounting pressure from healthcare stakeholders. The move aims to enhance affordability for diabetes and obesity treatments, crucial given the rising prevalence of these conditions globally.In gene therapy, BioMarin has faced challenges with its hemophilia A gene therapy, Roctavian. Despite potential clinical benefits, BioMarin's efforts to divest the therapy have resulted in a $240 million financial setback. This scenario underscores the inherent complexities and financial risks associated with developing advanced therapies like gene therapies. Meanwhile, Pfizer has shown continued interest in gene editing technologies by securing global rights to Beam Therapeutics' liver-targeted gene editing candidate. This decision marks Pfizer's strategic pivot towards promising frontiers in therapeutic innovation.Emerging biotech BreezeBio has rebranded and secured $60 million in funding to advance its research in genetic medicine focused on restoring immune tolerance in type 1 diabetes. This strategic pivot towards addressing autoimmune diseases using innovative genetic approaches highlights ongoing efforts within the biotech sector to tackle complex health challenges through cutting-edge science.Collectively, these developments illustrate dynamic trends within the pharmaceutical and biotech sectors: a shift towards more equitable global partneSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

"Why are we paying $10,000 for a $30 drug?"My guest this week is Pramod John, a former Silicon Valley tech entrepreneur who entered the healthcare space to tackle the largest economic problem in the country: skyrocketing healthcare costs. Pramod quickly realized that healthcare's dysfunction is actually not a technology problem - it is a deeply ingrained problem with economic incentives.In this episode, we dive into the murky waters of Pharmacy Benefit Managers (PBMs) and why the traditional model is designed to drive up costs rather than lower them. We discuss the shocking statistics of drug spend (where 2% of people account for 55% of the costs), why FDA approval doesn't always mean a drug is effective (using the infamous Alzheimer's drug as an example), and the implications of recent fiduciary lawsuits like the one against J&J.Pramod explains how we can bring common sense back to healthcare by treating drugs like any other consumer purchase. By utilizing an "open market" drug management model, he argues that we can effectively replace traditional PBMs with transparent transaction processing software - saving plans 30% to 50% without relying on restrictive formularies or rebate games. Tune in this week for a clear roadmap for how to actually fix the irrational economics of our healthcare system.Thank you to our 2026 sponsors!ParetoHealth: ParetoHealth empowers midsize employers with a long-term solution to reduce volatility and lower overall health benefits costs. Visit ParetoHealth.com to learn more.Samaritan Fund: A program that connects those who need help to the support they need. We are proud to offer the Samaritan Fund Program. Visit SamaritanFundProgram.com to learn more.Vālenz Health: We're Vālenz Health, your partner in improving health literacy, reducing plan spend, and delivering high-value healthcare. Visit ValenzHealth.com to learn more.Imagine360: Imagine360 helps self-funded employers save on healthcare with smarter health plans. Cut expenses by 20-30% with custom solutions. Contact us today at Imagine360.com.Chapters:(00:00:00) Intro: Why We Talk About Cost Instead of Quality (00:02:42) From Silicon Valley & Defense Tech to McKesson (00:10:43) Why Healthcare is NOT a Technology Problem (00:15:53) Fiduciary Responsibility & The J&J Lawsuit (00:19:03) The Butter Knife vs. Pareto: The Math of Drug Spend (00:23:54) Building an "Open Market" Alternative to PBMs (00:29:40) Why Doctors Fly Blind on Drug Pricing & Formularies (00:35:42) FDA Approval vs. Real-World Efficacy (00:45:44) How to Actually Fix the Model: The Real-Time "Pause" (00:58:36) Why International Sourcing & PAPs Aren't the Fix (01:11:00) Replacing PBMs with Simple Transaction SoftwareKey Links for Social:@SelfFunded on YouTube for video versions of the podcast and much more - https://www.youtube.com/@SelfFundedListen/watch on Spotify - https://open.spotify.com/show/1TjmrMrkIj0qSmlwAIevKA?si=068a389925474f02Listen on Apple Podcasts - https://podcasts.apple.com/us/podcast/self-funded-with-spencer/id1566182286Follow Spencer on LinkedIn - https://www.linkedin.com/in/spencer-smith-self-funded/Follow Spencer on Instagram - https://www.instagram.com/selffundedwithspencer/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of these industries, exploring significant regulatory shifts, scientific breakthroughs, and strategic corporate maneuvers that are shaping the future of healthcare.The pharmaceutical and biotech sectors are currently navigating a period of profound transition. Recent regulatory developments have captured attention, particularly the U.S. Supreme Court's decision to overturn emergency tariffs imposed by the previous administration. This ruling is pivotal as it alleviates financial pressures on the industry, allowing companies to redirect their resources towards innovation and development. It underscores the interconnectedness of global supply chains and highlights the importance of stable regulatory environments for fostering industry growth.In a notable advancement within oncology, AstraZeneca has achieved FDA approval for its combination therapy of Calquence and Venclexta as an all-oral regimen for first-line chronic lymphocytic leukemia (CLL). This approval not only positions AstraZeneca competitively in the BTK inhibitor market but also signifies a shift towards more patient-friendly treatment regimens. By simplifying therapy, this development promises to enhance patient compliance and improve outcomes, challenging existing standards in CLL care.Meanwhile, internal challenges at the Centers for Disease Control and Prevention have led to a postponement of a critical vaccine advisory panel meeting. This delay occurs amid evolving vaccine policies that have sparked debate within the public health community, potentially impacting immunization strategies and initiatives aimed at bolstering public health.Corporate governance within the industry is also experiencing shifts. Novo Nordisk has nominated two industry veterans to its board as part of an ongoing strategy to align leadership with evolving business objectives. Similarly, Roche is contemplating divesting its once-blockbuster antibiotic Rocephin in response to competitive pressures from generics in Europe. These moves reflect a broader industry trend where companies are re-evaluating their portfolios to better respond to market dynamics and patent expirations.Novartis is making strategic changes as well by selling its stake in Novartis India Limited while maintaining separate commercial and R&D interests in the region. This action highlights a growing trend among pharmaceutical giants towards streamlining operations and focusing on high-growth areas—a strategy aimed at maximizing resource allocation efficiency.Despite narrowly missing a $1 billion revenue target for 2025, Madrigal Pharmaceuticals remains optimistic about the growth prospects of its drug Rezdiifra within the metabolic dysfunction-associated steatohepatitis (MASH) market. The company anticipates further expansion driven by unmet medical needs, underscoring the competitive dynamics within this therapeutic area.In personnel movements that could influence strategic directions, Daiichi Sankyo has appointed former Novartis CMO John Tsai as head of its R&D division. His expertise is expected to bolster Daiichi's focus on oncology and other critical therapeutic areas, potentially accelerating innovation within their drug development pipeline.Meanwhile, Manus Bio has secured a $15 million contract with the U.S. government for domestic supply of shikimic acid, an essential component for producing Tamiflu. This contract highlights efforts to strengthen domestic pharmaceutical supply chains amid global uncertainties—a crucial consideration for ensuring medication availability during crises.In clinical research, a setback was observed with Grail's Galleri cancer blood test trial failing to meet its primary endpoint in collaboration with the NHS. The resulting decline in GrailSupport the show

In today's episode, we spoke with Alexander I. Spira, MD, PhD, FACP, FASCO. Dr Spira is co-director of the Virginia Cancer Specialists (VCS) Research Institute in Fairfax, director of the VCS Thoracic and Phase I Program, chief scientific officer of NEXT Oncology, and a clinical assistant professor at Johns Hopkins University in Baltimore, Maryland.In our exclusive interview, Dr Spira discussed the significance of the December 2025 FDA approval of amivantamab and hyaluronidase-lpuj (Rybrevant Faspro), also known as subcutaneous amivantamab, for the treatment of patients with EGFR-mutated non–small cell lung cancer (NSCLC) across all approved indications for amivantamab-vmjw (Rybrevant). He noted key data from the pivotal phase 3 PALOMA-3 trial (NCT05388669), which showed that subcutaneous amivantamab combined with lazertinib (Lazcluze) had a more favorable safety profile compared with intravenous (IV) amivantamab plus lazertinib and was noninferior to the IV formulation in terms of efficacy. Dr Spira contextualized these trial findings within the larger EGFR-mutated NSCLC treatment paradigm and explained how this formulation of amivantamab addresses a previously unmet patient need.

The landscape of hormone replacement therapy (HRT) and other medications is constantly evolving. Recently, the black box warning on HRT was removed, highlighting the importance of context when evaluating drug safety. From post-finasteride syndrome to FDA approval nuances, and the safety of compounding pharmacies, this guide explains what patients and providers need to know to make informed choices about hormonal and non-hormonal therapies.What You'll Learn in This Video1️⃣ HRT Black Box Update – Why the warning was removed and what it means for patients.2️⃣ Post-Finasteride Syndrome – Risks, neurological and sexual side effects, and global regulatory responses.3️⃣ FDA Approval vs. Safety – Why FDA approval doesn't always mean a product is risk-free.4️⃣ Compounding Pharmacy Regulation – How compounding works, safety standards, and legal customization of therapies.5️⃣ Non-Hormonal Options – Combining ingredients like DHEA, vitamins, and hyaluronic acid for safe, tailored alternatives.

In this episode of Disruption/Interruption, KJ sits down with Julian Circo, Co-Founder of Hyfe, a company revolutionizing respiratory health diagnostics through AI-powered cough monitoring. Julian shares his unconventional journey from humanitarian work in post-conflict zones to building the world's largest cough dataset—over 700 million samples. The conversation explores how Hyfe is transforming coughing from a subjective symptom into an objective, quantifiable biomarker, enabling better research, drug development, and patient care. Julian discusses the challenges of disrupting the conservative pharmaceutical industry, the surprising complexity of measuring coughs, and Hyfe's groundbreaking digital therapeutic for chronic cough sufferers. Four Key Takeaways [0:41] Coughing is Medicine's Most Common Yet Least Understood Symptom - Despite being the single most common symptom in medicine for over a century, medical science still cannot answer basic questions like "what is a normal amount of coughing for a healthy person?" Even top pulmonologists disagree significantly on this fundamental question. [11:27] Building the World's Largest Cough Dataset Required Creative Problem-Solving - Hyfe collected over 700 million cough samples by launching a free consumer app during COVID-19 that monitored coughs in the background. This approach solved the critical challenge of gathering diverse, real-world data across different demographics, environments, and microphones—essential for training accurate AI models. [21:52] Pharma's Resistance to Disruption is Actually Rational - The pharmaceutical industry's notorious resistance to innovation stems from legitimate needs: trials spanning months or years require consistent measurement methods to compare data over time. Hyfe succeeded by "leading with science" rather than pitching disruption, focusing on the measurable value they create. [27:30] A Digital Therapeutic Offers Hope Where 15 Drug Trials Failed - Over the past 13 years, 15 pharmaceutical molecules for chronic cough treatment have failed clinical trials. Hyfe is developing a digital therapeutic based on behavioral cough suppression therapy—similar to physical therapy for joints—that has already shown 40% efficacy in preliminary research, offering hope to the one in ten Americans suffering from chronic cough. Quote of the Show (4:28):"People innovate as a way of life. It’s not a luxury. You have to find ways to communicate. You have to find ways to access goods. You have to find ways to make do…” – Julian Circo Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Julian Circo: LinkedIn: https://www.linkedin.com/in/icirco/Company Website: https://www.hyfe.com/Failed Chronic Cough Candidates: https://support.hyfe.com/hubfs/HTML/failed_antitussives_timeline.htmlCoughPro: https://coughpro.com/ How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approval of T-DXd (trastuzumab deruxtecan) plus Pertuzumab for the treatment of HER2-positive metastatic breast cancer. Joined by Dr. Sara Tolaney, the lead author of the DESTINY-Breast 09 study, where we discussed the findings that show a significant improvement in progression-free survival (PFS) from 26.9 months to 40.7 months, with a hazard ratio of 0.56. Key topics included: • The design and findings of the DESTINY-Breast09 trial • Comparison with traditional treatment regimen THP (trastuzumab, pertuzumab, and taxane) • The implications of these findings for clinical practice • The role of maintenance therapy and the potential for personalized treatment strategies • Common side effects associated with T-DXd and pertuzumab, including ILD (Interstitial Lung Disease) Join us as we explore the future of HER2-positive breast cancer treatment and the exciting developments that are changing the landscape for patients. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/  Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights! #HER2positiveBreastCancer, #TrastuzumabDeruxtecan, #DestinyBreast09, #MetastaticBreastCancer, #OncologyBrothers

Bioelectronic medicine is changing how we treat inflammation, autoimmunity, and chronic disease, and this episode shows you exactly how nerve stimulation could redefine human performance, longevity, and brain optimization. You will learn how electricity, neurotransmitters, and targeted neural pathways can replace drugs, control inflammation, and help you hack the vagus nerve with precision instead of guesswork. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey is joined by Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes for Medical Research at Northwell Health, pioneer of vagus nerve research, and author of The Great Nerve. He is one of the world's most cited scientists in inflammation and neuroscience, and his discoveries created the field now known as bioelectronic medicine. He identified the therapeutic action of anti TNF antibodies, mapped the inflammatory reflex, and revealed how vagus nerve signaling controls immunity. With more than 450 scientific publications and over 120 U.S. patents, he is a trusted authority whose work drives the future of anti-aging, functional medicine, metabolism, and neural therapies. Dr. Tracey and Host Dave Asprey explore how the vagus nerve truly operates, why it contains 200,000 fibers with different functions, and what happens when you stimulate specific pathways that regulate inflammation, HRV, neurotransmitters, and immune signaling. You will learn how nerve impulses transmit information, how voltage gated ion channels shape behavior and biology, and why certain forms of stimulation create measurable improvements in mitochondria, metabolic control, sleep optimization, and emotional regulation. They break down the science behind surgical vagus nerve implants, focused ultrasound, gamma entrainment, cytokine control, and real neuromodulation. They also explore why cold plunging, breath work, HRV training, nootropics, and consumer devices vary so widely in their effects, and how to evaluate these tools with practical biohacking frameworks. You will hear what actually works, what remains experimental, and what the next decade of nerve based therapies could unlock for brain optimization, longevity, ketosis, fasting, supplements, and AI guided interventions in human biology. You'll Learn: • How vagus nerve stimulation reduces inflammation through the inflammatory reflex • Why bioelectronic medicine can replace drugs in autoimmune conditions • How nerve fibers relay electrical and chemical signals inside the body • Why cold immersion, breath work, and HRV training activate specific vagal pathways • How 40 hertz gamma entrainment may influence cognitive decline • Which stimulation methods have clinical validation and which do not • Why high vagal tone is linked to better metabolism, immunity, and emotional stability • What future nerve based technologies may unlock for human performance Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: Kevin J. Tracey, vagus nerve stimulation, bioelectronic medicine, inflammatory reflex, SetPoint Medical, cytokine control, neuromodulation therapy, autonomic nervous system, HRV optimization, inflammation reduction, rheumatoid arthritis treatment, focused ultrasound therapy, gamma entrainment, mitochondrial signaling, anti-aging science, neural pathway hacking, functional medicine research, immune system regulation, brain and body performance, human longevity science Thank you to our sponsors! -AquaTru | Go to https://aquatruwater.com/daveasprey and save $100 on all AquaTru water purifiers. -MASA Chips | Go to https://www.masachips.com/DAVEASPREY and use code DAVEASPREY for 25% off your first order. -Timeline | Head to https://www.timeline.com/dave to get 10% off your first order. -Calroy | Head to https://calroy.com/dave for an exclusive discount Resources: • Learn More About Kevin's Work: https://feinstein.northwell.edu/institutes-researchers/our-researchers/kevin-j-tracey-md • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 - Trailer 1:12 - Bioelectronic Medicine 3:23 - FDA Approval 6:48 - RA Treatment Explained 11:35 - Vagus Nerve Function 15:12 - External vs Implanted Stimulation 18:06 - Focused Ultrasound 26:11 - Ear Stimulation Science 30:51 - Clinical Evidence 37:10 - Alzheimer's Link 42:15 - Future Applications 46:48 - Cold Exposure Effects 53:51 - Common Misconceptions 55:38 - Final Thoughts See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.